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Abstract 
 
 While the etiology of ovarian cancer (OC) is not completely understood, evidence 
suggests that chronic inflammation may promote malignant transformation.  However, 
familial history remains the strongest risk factor for developing OC and is associated with 
germline BRCA1 mutations, such as the 185delAG mutation.  Normal human ovarian 
surface epithelial cells expressing the 185delAG mutant, BRAT, exhibit molecular and 
pathological changes that may contribute to OC oncogenesis.  In the current study, I 
sought to determine whether BRAT could promote an inflammatory phenotype by 
investigating BRAT’s impact on the expression of the proinflammatory cytokine, 
Interleukin-1β (IL-1β).  Using a culture model system of normal human ovarian surface 
epithelial (OSE) cells with and without the BRCA1 185delAG frameshift mutation, 
BRAT, I investigated BRAT’s role in IL-1β expression.  OSE cells stably expressing the 
185delAG mutation and ovarian surface epithelial cells with endogenous 185delAG were 
analyzed for differential target gene expression by real time PCR, western blot, ELISA, 
luciferase reporter and siRNA assays.  Normal and malignant breast epithelial cell lines 
transiently expressing BRAT were also evaluated by real time PCR to determine whether 
BRAT-induced IL-1β expression is tissue specific.  BRAT-expressing OSE cells 
exhibited enhanced IL-1β mRNA and protein expression.  However, expression of BRAT 
in all breast cell lines failed to significantly alter IL-1β expression levels so that BRAT-
mediated IL-1β expression promoting a chronic inflammatory phenotype conducive to 
malignant transformation may be limited to the ovary.  Secondly, since OSE cells 
xi 
 
expressing the BRCA1 185delAG mutation have increased levels of IL-1β that may 
contribute to malignant transformation, in a pilot study, I sought to assess whether 
elevated urinary levels of IL-1β are associated with OC as well as compare urinary IL-1β 
levels with clinical parameters.  Urinary and serum levels of IL-1β were analyzed by 
ELISA and biostatistical analysis from a patient cohort consisting of healthy women 
(N=10), women with ovarian benign disease (N=23), women with OC (N=32), women 
with other benign gynecological conditions (N=22), and women with other gynecological 
cancers (N=6).  Urinary IL-1β levels were elevated in patients with ovarian benign 
disease and a first degree family history of ovarian and/or breast cancer.  Urinary IL-1β 
levels were also correlated with increased body mass index.  Urinary and serum IL-1β 
levels were increased in ovarian benign and OC patient samples supporting the theory of 
elevated urinary IL-1β being associated with cancer progression.  Lastly, I sought to 
begin early molecular characterization of BRCA1 185delAG to better understand its role 
in ovarian transformation.  I isolated 185delAG protein expressed in E. coli and utilized 
web tools to analyze the amino acid sequence to determine the molecular and structural 
characteristics.  The study results showed the predicted BRCA1 185delAG protein 
product is an ordered, self-aggregating, alpha helical protein structurally and molecularly 
distinct from wild-type BRCA1.  The BRCA1 185delAG amino acid sequence contained 
domains with resemblance to the Peptidase M20 family.  Isolation of the BRCA1 
185delAG protein product will allow for further protein analysis to better understand its’ 
oncogeneic functions; as well as, elucidate the mechanism of tissue-specific BRAT-
mediated IL-1β expression since increased IL-1β expression may represent an early step 
contributing to OC. 
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Chapter 1: 
 
Background 
Overview of Ovarian Cancer  
Ovarian cancer (OC) is the fifth leading cause of cancer death among women after lung, 
breast, colorectal, and pancreatic cancer [1].  It is estimated that 22,240 new cases will be 
diagnosed in the U.S. and that 14,000 women die annually from this disease [2].  The one year 
survival rate for OC can be as high as 79% [3]; and when diagnosed in an early stage the 5-year 
survival rate is 92% [1]. However, when diagnosed at a later stage, the 5-year survival is 
generally no better than 27% [1]. The high mortality associated with this disease is generally 
attributed to the fact that most cases typically present in late stage when OC has already spread 
beyond the ovary, that the disease is generally asymptomatic in early stages, and that an effective 
screening test is lacking [4, 5].  In addition to involving the ovary, ovarian epithelial cancer cells 
are shed into intraperitoneal ascites fluid and easily disseminate throughout the peritoneal cavity 
with preferential metastasis to the omentum and peritoneum as well as other local organs.  
However, familial history is the strongest risk factor for the development of OC and the majority 
of hereditary OCs are associated with mutation of the tumor suppressor breast cancer 
susceptibility gene 1 (BRCA1) [6].  Carriers of the BRCA1 mutation have a 30% risk of 
developing OC during their lifetime [7]. 
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Clinical Management of Ovarian Cancer 
OC is most often diagnosed in late stage due to nonspecific symptoms in early stages and 
a lack of adequate screening methodologies.  OC is symptomatic even in early stages with 89% 
of stage I & II patients reporting bloating, gas pains, pelvic discomfort, and urinary frequency 
[8].  However, these symptoms can often be confused with other more common disorders or can 
be attributed to benign gastrointestinal, genitourinary, musculoskeletal, or gynecologic disorders 
[8].  Furthermore, even when presenting with such symptoms, there is a lack of adequate 
screening methodologies.  Current detection methods include serum tumor markers such as 
CA125, imaging such as transvaginal ultrasound, and physical examination [9].  To date, the best 
screening method is a combination of serum CA125 levels and transvaginal ultrasound [10]; 
however, CA125 levels are still only elevated in 50-60% of sera from patients with stage I 
disease [11]. 
Optimal cytoreduction followed by platinum based chemotherapy remains the mainstay 
of therapy in the management of advanced epithelial OCs [12]. However, while the response rate 
to primary chemotherapy can be as high as 76%, response rate is dramatically reduced after 
relapse of disease [13]. Platinum resistance, defined as disease recurrence less than six months 
from completion of therapy is an important prognostic predictor. Patients with platinum-resistant 
tumors have a response rate of less than 10% when retreated with platinum compounds [14, 15] 
and alternative options also have poor response rates of 18-30% [16-23]. 
 
Etiology of Ovarian Cancer 
The majority of OCs are sporadic in origin, but about 10% of all epithelial ovarian 
carcinomas are associated with a hereditary predisposition and are characterized by an increased 
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incidence and earlier onset of disease [24]. Epidemiological studies suggest that, besides race 
[25] and familial history of breast or OC [26-28], events associated with ovarian surface 
epithelium (OSE) traumatization may result in aberrant OSE growth leading to ovarian epithelial 
carcinogenesis [29]. Thus, increased age, reproductive history (nulliparity), early menarche, late 
menopause and fertility drug use increase the risk for OC. In contrast, suppression of ovulation 
by pregnancy, lactation or oral contraceptive use decrease the risk for OC. Lifestyle factors 
including dietary fat intake and smoking may also increase the risk for OC while dietary intake 
of vitamins A,C, D and E may protect against OC [4, 30, 31].  
Consequently, there are four traditional hypotheses on the etiology of OC.  (1) Incessant 
ovulation: damage during ovulation and repair makes the OSE more susceptible to errors in 
DNA replication.  Decreased number of ovulation cycles resulting from long term oral 
contraceptive use, high parity, and lactation decreases the risk of OC; while early menarche and 
late menopause are risk factors for developing OC (Reviewed in [32]).  (2) Gonadotropin 
stimulation: hormones FSH and LH promote growth, and increased cell divisions and mutations; 
furthermore, FSH upregulates oncogenes (Reviewed in [32]).  However, this has become more 
controversial as studies show no relationship between circulating FSH and OC risk in 
postmenopausal women [33]; as well as, reduction of OC risk with higher circulating FSH [34].  
(3) Hormonal stimulation: high concentrations of androgens in the tumor microenvironment 
promote carcinogenesis, while progestins decrease the risk of OC.  Polycystic ovarian syndrome 
which results in high levels of circulating androgens increases the risk of OC and progestin use 
induces OSE cell apoptosis (Reviewed in [32]).  (4) Inflammation: damaged OSE induces 
inflammation and promotes reconstruction and mutation susceptibility (Reviewed in [32]).  
Events promoting chronic inflammation in the pelvic region appear to promote malignant 
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transformation [35-39], while non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) may 
be protective against OC [40-43]. 
Since OC is a heterogeneous disease composed of different tumor types with differing 
pathological features and behaviors, a dualistic model has additionally been proposed to 
categorize OC tumors based upon morphological and molecular genetic studies into two groups: 
type I and type II [44-46].  Type I tumors are comprised of low-grade serous carcinomas, low-
grade endometrioid, clear cell, and mucinous carcinomas.  These low-grade tumors develop in a 
stepwise manner from precursor lesions, such as borderline tumors and endometriosis, to 
malignancy.  They usually are confined to the ovary (stage 1) and have a good prognosis.  Type I 
tumors are more genetically stable and typically display a variety of somatic mutations that 
include KRAS, BRAF, and PTEN but very rarely TP53.  Type II tumors are highly aggressive and 
most often present in advanced stage (stage III and IV) resulting in a poor outcome.  Type II 
tumors account for approximately 75% of all epithelial OCs and are diagnosed as high-grade 
serous, high-grade endometrioid, malignant mixed mesodermal tumors, and undifferentiated 
carcinomas.  They are chromosomally unstable and have TP53 mutations in more than 95% of 
cases; and rarely display the mutations found in type I tumors.  Type II tumors have BRCA 
inactivation, either by mutation or promoter methylation, which occurs in up to 40% to 50% of 
high-grade serous carcinomas.  Inactivation of BRCA has not been reported in type I tumors.   
 
Ovarian Cancer Cell Origin 
Over 85% of OCs arise from and/or involve the OSE [12, 47].  Due to the common 
embryonic origin of OSE with the epithelia lining fallopian tube, endometrium and cervix, 
histologic subtypes of OSE-derived tumors include serous, endometrioid, and mucinous tumors, 
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respectively.  Likewise, the expression of stromal characteristics by OSE cells may be related to 
their shared mesodermal origin from the coelomic epithelium and to their close developmental 
relationship to ovarian stromal fibroblasts.  For example, OSE express both vimentin and keratin 
intermediate filaments characteristic of connective tissue and epithelium, respectively [48].  
Further, when maintained on collagen type I gel, OSE cells undergo a modulation into a spindle-
like morphology which accompanies collagen gel contraction [49].  In contrast, OSE cells invade 
Matrigel and can remodel extracellular matrix (ECM) by secretion of collagenase, gelatinase and 
stromelysin as well as produce laminin and collagens I, III and IV [50, 51].  Consequently, the 
interaction with stroma and the ability of OSE to produce, lyse and reconstruct ECM indicates 
that OSE has the capacity to undergo epithelial-mesenchymal conversions which may not only 
be necessary for restoring the integrity of the OSE following ovulatory damage, but may also 
contribute to invasion and metastasis with malignant transformation of the OSE.   
However, more recently the epithelial lining of the fallopian tube fimbriae has been 
implicated as the site of OC origin and the OSE as a secondary site of metastasis [45].  Several 
studies of prophylactic salpingo-oophorectomy in BRCA mutation carriers have found the 
earliest forms of serous carcinomas more frequently in the fallopian tube than in the ovary [52-
54].  Non-malignant fallopian tube epithelium collected in the luteal stage of the menstrual cycle, 
when the epithelium is exposed to follicular fluid after ovulation, was molecularly similar to high 
grade serous OC in BRCA mutation carriers [55].  Furthermore, gene expression profiles 
indicated an increased expression of proinflammatory genes, including interleukin-8 (IL-8) and 
tumor-promoting NF-κB target genes [56].  In confirmation, an ex vivo culture model of bovine 
fallopian tube epithelium exposed to human follicular fluid demonstrated increased expression of 
inflammation genes [57].    
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An all-encompassing theory now proposes that the adnexal peritoneum, fallopian tubal 
epithelium, and OSE be viewed as a single and central unit for ovarian  oncogenesis since these 
structures all originate in the mesodermally-derived embryonic coelomic epithelium [58].  
Epithelial transitions between sites represent areas with enhanced susceptibility toward neoplasia 
[59].  In support, other epithelial transitions that play a role in neoplasia include the cervical 
squamocolumnar [60], gastroesophageal [61], and anorectal junctions [62].  By 
immunohistochemistry, Seidman, et. al. showed evidence of transitional cell metaplasia, chronic 
inflammation, and mesothelial hyperplasia at the fallopian tube-peritoneal junction 
(tuboperitoneal junction) where serous epithelium meets the peritoneal mesothelium [63].  They 
also suggested similar epithelial transitions may be located where tubal-type epithelium borders 
mesothelium in OSE inclusions and in the cell adhesions on the ovarian surface that form gland-
like and cystic spaces lined by peritoneum and serous epithelium [63].  Kuhn, et. al. suggested 
benign Brenner tumors may arise from the transitional metaplasia of the tuboperitoneal junction 
and seed to the ovary [64].  Lastly, epithelial transitions may host novel stem cell niches for OSE 
regeneration that are prone to malignant transformation [65].   
 
Inflammation and Ovarian Cancer 
 During tissue repair following ovulation, OSE undergoes epithelial-mesenchymal 
transition (EMT) in response to its local microenvironment assuming a fibroblast-like phenotype 
which promotes OSE migration, proliferation and matrix remodeling. ‘Incessant ovulation’ 
proposes that repeated injury to the OSE with subsequent rounds of cellular proliferation can not 
only lead to the acquisition of replicative DNA errors contributing to genetic instability and 
ensuing malignant transformation [66], but also to chronic inflammation [67].  Such 
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inflammation is associated with oxidative stress and recruitment of activated immune cells, 
including macrophages, T cells, B cells, natural killer cells, neutrophils, and granulocytes [68] 
resulting in a locally marked increase in cytokines/chemokines (interleukins and tumor necrosis 
factors) and matrix-remodeling enzymes (plasminogen activators and collagenases) that can also 
promote tumor formation [66].  In addition to presenting as an inflammatory disease, 
inflammation of the ovarian epithelium has been associated with increased risk for OC [67, 69-
71] and endometriosis is associated with risk for clear cell carcinoma of the ovary [72-76]. 
Consequently, the potential clinical contribution of inflammatory mediators, including 
interleukin-6 (IL-6) and IL-1, for ovarian tumor initiation and progression should not be 
overlooked (summarized in Table 1.1).  
 
Interleukin-6 
 IL-6 is a pleiotropic cytokine that plays a major role in the immune system in response to 
injury and infection, as well as, inflammation [77].  IL-6 is produced by T cells, monocytes, 
fibroblasts, endothelial cells, and keratinocytes [78].  Depending on the experimental system, IL-
6 has been suggested to have both proinflammatory and anti-inflammatory properties in vitro and 
in vivo [79].  However, it appears that IL-6 acts predominately as an anti-inflammatory and 
immunosuppressive cytokine by directly suppressing IL-1 and tumor necrosis factor-α (TNF-α), 
inducing release of glucocortoids, and inducing natural antagonists to IL-1 and TNF-α [79].  In 
an in vitro prostate cancer model, cancer-associated fibroblasts secreted higher amounts of IL-6 
than normal fibroblasts which resulted in an increased proliferation of normal epithelial cells and 
increased endothelial cell migration towards the cancer-associated fibroblasts and/or their 
conditioned media through transwell migration assay [80].  It is not surprising then that Spaeth et  
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Table 1.1 Proposed Functions of IL-6 and IL-1 in OC 
(Table from [103]) 
  
Cytokine Inflammatory 
Function 
Proposed Function in OC Model Ref. 
IL-1α Proinflammatory • Stimulate angiogenesis 
• Recruit immunocompetent cells 
 
• Increase platelet count 
 
 
• In vitro/In vivo 
• In vitro/In vivo 
 
• Phase I 
clinical trial 
• [81] 
• [82-87]  
• [88, 89] 
IL-1β Proinflammatory • Increase expression of MMP-1 
• Stimulate production of pro-
angiogenic factors 
• Promote OC cell migration & 
invasion 
 
• In vitro 
• In vitro 
 
• In vitro 
• [90] 
• [91] 
 
• [92] 
IL-1Ra Anti-
inflammatory 
• Antagonist to IL-1α & IL-1β 
• Abundant in the OC ascites 
 
• In vivo 
 
• [93] 
• [84, 94] 
IL-6 Anti-
inflammatory 
• Promote OC cell proliferation 
• Stimulate angiogenesis 
• Enhance endothelial cell 
migration 
• Increase OC cell lines capacity 
to secrete MMP-9 
• Increase chemotactic and/or 
chemokinetic activity 
• Increase invasiveness 
• Induce chemoresistance 
• Increase platelet count 
• In vitro 
• In vitro/In vivo 
• In vitro/In vivo 
• In vitro 
 
• In vitro 
 
• In vitro 
• In vitro/In vivo 
• Phase I & II 
clinical trial 
• [95] 
• [96] 
• [96] 
• [97] 
 
• [98] 
 
• [98] 
• [77, 99, 
100] 
• [101, 
102] 
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al. found that tumor associated fibroblasts derived and differentiated from mesenchymal stromal 
stem cells produced and secreted IL-6 that similarly promoted OC cell proliferation [95]. 
In the normal ovary, aside from production by activated stromal immune cells, IL-6 is 
produced by granulosa cells [104] and OSE cells [105, 106].  However, neoplastic ovarian cells 
also routinely overexpress IL-6 in vitro [105-107] and greater amounts of IL-6 are present in the 
cystic fluid of malignant tumors when compared to cystic fluid of benign tumors [78].  Likewise, 
OC ascites are rich in IL-6 [99, 108-110].  Consequently, elevated levels of IL-6 in the blood and 
ascites are associated with poor prognosis in OC [111].   
While the role of IL-6 in the etiology of OC is not fully understood, we might predict that 
IL-6 contributes to OC by promoting angiogenesis, tumor invasion, and chemoresistance.  
Specifically, in vivo treatment with IL-6 induced angiogenesis and enhanced endothelial cell-
mediated migration of human ovarian carcinoma cells [96].  IL-6 may also be involved in the 
tumorigenic processes of OC cell lines by increasing their capacity to secrete matrix 
metalloproteinase-9 [97].  Further, OC cell lines cultured with IL-6 demonstrate increased 
chemotactic and/or chemokinetic activity and increased overall invasiveness [98].  
Overexpression of IL-6 is also associated with chemoresistance in OC cells [99, 100].  In vitro 
studies of OC cell lines further show that autocrine production of IL-6 decreased their 
responsiveness to cisplatin and paclitaxel [77].  Interestingly, elevated serum IL-6 levels are 
uniquely associated with OC compared to other gynecological malignancies and although this is 
a much less sensitive biomarker for OC than CA125 [99], it may still serve as a useful prognostic 
indicator of disease aggressiveness and/or responsiveness to chemotherapy. 
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Interleukin-1 
There are 11 members of the IL-1 cytokine family that have proinflammatory or anti-
inflammatory activity.  The most thoroughly studied cytokines from this family are two agonist 
cytokines: IL-1α & IL-1β, and one antagonist cytokine: interleukin-1 receptor antagonist (IL-
1Ra). Though all of these cytokines are associated with chronic inflammatory diseases (CIDs), 
IL-1β appears to be the primary mediator of inflammation in CIDs [93].   
IL-1β is synthesized in a precursor form as a 31kD protein that is cleaved by caspase-1 
into its active 17kD mature secreted form [112].  IL-1β is mainly produced by monocytes and 
macrophages, but can also be produced by endothelial cells, fibroblasts, and epidermal cells in 
response to bacterial or innate immunity stimulation [113].  Both normal and malignant epithelial 
ovarian cells also produce IL-1 [111], although activated immune cells in the stroma remain the 
major source of IL-1 [114].  Constitutive production of IL-1β by ovarian carcinoma cells [115] 
enhances their invasion capacities by increasing expression of matrix metalloproteinase-1 [90] 
and stimulating production of pro-angiogenic factors such as vascular endothelial growth factor 
(VEGF) [91].  Additionally, fibroblasts cultured with conditioned media from a highly metastatic 
OC cell line or with IL-1β induced transformation of the fibroblasts to myofibroblasts expressing 
α-smooth muscle actin (α-SMA) [92]. This coincided with induction of myofibroblast expression 
of fibroblast activation protein (FAP), a cell-surface serine protease with capacity to remodel 
ECM by cleaving collagen type 1 [92], thereby promoting OC cell migration and invasion.   
IL-1α is likewise synthesized in a precursor form as a 31kD protein that is cleaved by 
Ca2+-dependent protease calpain into an active 17kD mature cell-associated form [87, 112].  IL-
1α is produced by monocytes, macrophages, epithelial cells, keratinocytes, and fibroblasts [116].  
However, because it remains mainly cell-associated, IL-1α induces less inflammation and 
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angiogenesis than IL-1β [81].  Further, since IL-1α is generally secreted to a lesser extent than 
IL-1β, it is not commonly detected in bodily fluids except when released from necrotizing cells 
in cases of severe inflammation [87].  In its cell-associated form, IL-1α mainly acts as a tumor 
suppressor in malignant cells by recruiting immunocompetent cells to the tumor 
microenvironment and assisting in an immunologic response to combat tumor growth [82-84, 
87].  IL-1α tumor suppressor characteristics have been further confirmed in vivo where IL-1α 
produced by tumorigenic fibroblasts decreased the number of tumor growths, as well as 
increased tumor rejection by facilitating activation and expansion of helper T cells [85, 86].  
Consequently, in OC, IL-1β generally promotes invasiveness, tumor angiogenesis, and induces 
immune suppression while IL-1α reduces tumorigenecity by inducing antitumor immunity [117].   
Lastly, IL-1Ra is an antagonist that inhibits IL-1α and IL-1β from binding to both IL-1 
receptors, but does not activate IL-1 receptor cell signaling cascades.  IL-1Ra is secreted by the 
same cell types as IL-1α and IL-1β including, monocytes, macrophages, and OSE [118].  
Further, high levels of IL-1Ra in cultured tumor-derived macrophages compared to cultured 
tumor-derived ovarian epithelial cells [119] suggest that the major contributors of IL-1Ra are 
activated macrophages. IL-1Ra is excessively abundant in the ascites of late-stage OC patients 
compared to IL-1Ra levels in ascites and/or serum levels from early-stage OC and benign 
ovarian tumors [94].  Higher levels of IL-1Ra in ascites and/or serum appear associated with 
poor prognosis and reduced overall survival [94].  Since IL-1Ra does not activate IL-1 receptor 
cell signaling cascades and IL-1Ra production can be induced by IL-1β and/or IL-1α, it is 
plausible that the increased IL-1Ra in the ascites and the associated poor prognosis is due to 
secreted IL-1β signaling [84].  In agreement, Mustea et. al. found that increased levels of IL-1β 
in the serum and/or ascites was associated with decreased survival [94].   
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 Interestingly both IL-6 and IL-1 levels are elevated in ascites.  In vitro studies show that 
treatment of granulosa cells with IL-1 increases IL-6 production in a dose-dependent manner 
[104] and,  likewise, treatment of OC cell lines with IL-1β, led to increased secretion of IL-6 
[120].  Consequently, the contribution of IL-1 to initiate and promote OC progression by 
regulating IL-6 expression deserves consideration. 
 
BRCA1 
Familial history is the strongest risk factor for the development of OC and the majority of 
hereditary OCs are associated with mutation of the tumor suppressor breast cancer susceptibility 
gene 1 (BRCA1) [6].  Women with inherited mutations of BRCA1 have a 40-60% lifetime risk 
of OC and 11-27% lifetime risk of breast cancer [121-125].  The BRCA1 gene is located on 
chromosome 17q21 [126] and is composed of 22 coding exons distributed over ~100kb of 
genomic DNA [127].  The BRCA1 gene encodes a large protein 1863 amino acids in length 
[127].  The BRCA1 protein contains an N-terminal RING motif, that interacts with BRCA1-
associated RING domain protein 1 (BARD1) to form an E3 ligase, and two BRCA C terminus 
(BRCT) motifs that form a phosphoprotein recognition domain [128-131].  The BRCA1 protein 
contains a DNA-binding domain [132, 133]; and in its central region, a SQ-cluster domain 
(SCD), the preferred site of ATM phosphorylation that is required for efficient DNA double 
strand break repair [134].  It also has two nuclear localization signals (NLS) [135, 136] and a 
nuclear export signal (NES) [137] necessary for the predominately nuclear BRCA1 protein to 
shuttle between nuclear and cytoplasmic compartments [138, 139].   
BRCA1 plays a role in DNA damage response, cell cycle signaling, recruitment of 
chromatin modifying proteins, interaction with transcription factors, and ubiquitin ligase activity; 
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and the loss of these functions may contribute to the development of cancer by promoting 
genomic instability and accumulation of cancer-causing mutations [140].  BRCA1 recognizes 
DNA damage and is involved in the DNA repair process via interactions with RAD51 [141, 
142].  In normal cells, BRCA1 and RAD51 are essential for genomic stability predominately 
through the homologous recombination pathway [134] in the repair of double-strand DNA 
breaks.  BRCA1 modulates the cell-cycle at the G2/M checkpoint [143].  In breast cancer cells, 
BRCA1 polyubiquitinates cyclin B and Cdc25C, two G2/M cell cycle proteins, and targets the 
proteins for degradation by the ubiquitin-proteasome pathway in an APC/C-independent manner 
[144].  BRCA1 is shown to maintain heterochromatin structure via ubiquitination of core histone 
H2A [145].  Reports have shown that BRCA1 physically interacts with histone acetyltransferases 
(HATs), p300 and CREB-binding protein (CBP) [146, 147]; and, these interactions work to 
enhance transcriptional activity of BRCA1 [148].  BRCA1 also functions as either a co-activator 
or co-repressor of transcription through its interactions with c-Myc [149], activating transcription 
factor 1 [150], and signal transducers and activators of transcription 1 [151] modulating their 
activity.  BRCA1 has also been found to bind the p65/RelA subunit of the nuclear factor-κB 
(NF-κB) and stimulate the tumor necrosis factor-α (TNF-α) and the IL-1β-induced transcription 
of NF-κB target genes; suggesting BRCA1 plays a role in cell survival and cell death following 
cell stress [152]. 
Mouse models have been used to study the tumor suppressor functions of BRCA1.  
Deficiency in BRCA1 gene expression results in early embryonic lethality [153-155]; however, 
mouse models carrying allelic mutations of BRCA1 to overcome embryonic lethality resulted in 
cells with genomic instability and defects in DNA damage repair [154].  Still, the loss of BRCA1 
alone did not lead to tumorigenesis; there was a necessity for multiple genetic alterations, 
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including the inactivation of p53 and the activation of oncogenes caused by genomic instability 
for tumorigenesis [154].  Ongusaha, et. al. showed BRCA1 plays a role in p53-directed growth 
suppression when both are coexpressed resulting in an irreversible senescence-like phenotype in 
vitro [156].  Shakya, et. al. studied BRCA1-mediated tumor suppression in genetically 
engineered mouse models and found the BRCT phosphoprotein recognition domain to be critical 
for BRCA1-mediated tumor suppression [157].  A RING mutation (C61G) disrupts the 
BRCA1/BARD1 heterodimer and abrogates ubiquitin ligase activity [131, 158-160].  Mice 
homozygous for the C61G mutation with a mutated p53 background were found to more rapidly 
develop tumors than in mice carrying a BRCA1-null allele [161].   
There are several types of risk-associated mutations, including missense mutations, 
truncating mutations, and larger genomic alterations.  Reported risk-associated missense 
mutations primarily occur in the RING and BRCT domains which are both known to be involved 
in functionally important protein-protein interactions [162].  The more frequently reported 
truncating mutations occur due to small insertion and/or deletion events that result from 
nonsense mutations and frameshifts [162].  Larger genomic alterations are rearrangements that 
result in duplications or deletions of one or more exons that can often produce a premature stop 
codon and may represent 7-40% of all BRCA1 mutations identified [162].  Hereditary mutation 
carriers have one germline mutation and later in life develop a secondary somatic mutation in the 
tumor through the loss of heterozygosity [163].  The loss of heterozygosity and p53 inactivation 
seem to be early events in the induction of hereditary OC [164].   
In the study of hereditary OC and inherited BRCA1 mutations, founder mutations are 
very important.  Founder mutations are mutations with a high frequency in individual alleles that 
are particular to a specific population [162].  These mutations occur when small groups of 
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isolated people undergo a dramatic population decrease with subsequent interbreeding and 
consequent reduced genetic variability; that results in a normally rare mutation continuing to be 
present and becoming more common within the population [165].  A well-known example of the 
founder effect are the Ashkenazi Jews with ancestors from Eastern and Central Europe, including 
Germany, Poland, Lithuania, Ukraine, and Russia [165].  Three of the best characterized BRCA1 
and BRCA2 founder mutations are found in the Ashkenazi Jewish population: BRCA1 
185delAG, BRCA1 5382insC, and BRCA2 6174delT [162, 166].  These three mutations 
represent the majority of germline BRCA1 and BRCA2 mutations found in the Ashkenazi 
Jewish population [167, 168].  These mutations are seen in 2.6% of the Ashkenazi Jewish 
population in comparison to 0.2% of BRCA1/BRCA2 mutation carriers in the general population 
[169, 170]; however, they contribute to 24-62% of Ashkenazi Jewish OC cases [166, 171, 172].       
BRCA-associated hereditary OC is associated with favorable patient outcome in 
comparison to sporadic OC due to enhanced initial chemosensitivity that is lost at disease 
recurrence [173-176].  Also, enhanced chemosensitivity has been seen in OC with low BRCA1 
expression [177, 178].  Promoter methylation status has been implicated to play a role in the 
enhanced chemosensitivity; however, this is still a controversial assertion.  BRCA1 promoter 
methylation has been associated with enhanced sensitivity to platinum-based chemotherapy in in 
vitro and xenograft models [179].  Another study found increased survival time in patients with 
methylated BRCA1 promoter and fewer cases of recurrent epithelial OC in patients with 
methylated BRCA1 promoter suggesting that BRCA1 promoter methylation is predictive for 
response to platinum-taxane-based chemotherapy [180].  In opposition, investigation of 316 OC 
patients found neither BRCA1 mutation status nor its promoter methylation has been associated 
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with patient outcome [181].  Two other clinical trials likewise found no correlation between 
BRCA1 promoter methylation and chemosensitivity [182, 183]. 
BRCA1 mutations can result in complete or partial loss of wild-type function.  However, 
there are BRCA1 mutations that result in protein products that may have functions independent 
of wild-type BRCA1 or in competition to wild-type BRCA1 function.  For instance, the 
5677InsA insertion mutation, which results in a frameshift and premature stop signal at codon 
1853, inhibits proliferation of human prostate cancer cells more efficiently than endogenous 
wild-type BRCA1 [184].  The ability of wild-type BRCA1 to enhance apoptosis in breast and 
OC cells was inhibited when co-expressed with BRCA1 mutations, 5382InsC and 5677InsA 
[185].  The BRCA1 mutant, 185delAG, results in a 66% lifetime risk of developing OC [186].  
The  BRCA1 185delAG Amino Terminal truncated protein or BRAT is a result of a deletion of 
two nucleotides (AG) in the second exon of the BRCA1 gene leading to a reading frame shift 
and a premature stop codon at exon 39; as well as, complete loss of the BRCT motifs.  BRCA1 
gene mutations resulting in a premature stop codon are generally susceptible to nonsense-
mediated messenger RNA (mRNA) decay.  However, 185delAG and 5382InsC, were found to 
be unaffected by mRNA decay [187, 188]. 
In order to improve survival rates, it is necessary to determine the elements involved in 
premalignant changes leading to early stage oncogenesis in the possibility of determining 
additional cancer markers for early stage diagnosis. The greatest confounder to understanding 
premalignant changes leading to early stage disease is an unknown etiology.  One obstacle to 
understanding OC etiology is the lack of an appropriate experimental mouse model.  While 
researchers have been able to induce ovarian-like tumor models in certain genetically-altered 
mice or genetically-altered cell lines injected into mice, the reoccurring limitation is an inability 
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for the disease to be inherited by the progeny leading to spontaneous OC formation (reviewed in 
[189]).  The spontaneous formation of heritable OC is required to observe the changes from 
premalignancy to malignancy.   
 
Rationale 
Previously, we demonstrated that OSE from carriers of the BRCA1 185delAG mutation 
exhibited enhanced apoptosis and caspase 3 activation in response to stauosporine [190].  In 
order to rule out the possibility that these features were due to the loss of bi-allelic BRCA1 gene, 
BRAT was expressed in OSE cells with endogenous wild-type bi-allelic BRCA1 gene.  In 
agreement, BRAT cells also exhibited enhanced caspase 3-mediated apoptosis; as well as, 
diminished levels of phospho-Akt, cellular inhibitor of apoptosis 1 (cIAP1), and X-linked 
inhibitor of apoptosis protein (XIAP) [191].  Further, we found that BRAT upregulated 
expression of the tumor suppressor maspin and correlated with enhanced chemosensitivity [192].  
By contributing to apoptosis, invasion and metastasis, maspin has been correlated with cisplatin 
sensitivity in OC cell lines and increased overall survival times in OC patients [193].  Lastly, we 
have also shown that matrix metalloproteinase-1 (MMP1) is transcriptionally upregulated in a c-
Jun-dependent manner and that BRAT OSE cells or BRCA1 185delAG OSE cells secrete 
enhanced levels of MMP1 (Linger, publication in progress). 
These studies taken together demonstrate that the BRCA1 185delAG mutation mediates 
unique molecular and cellular changes in OSE cells independent of the loss of endogenous 
BRCA1 function.  These changes could impact the physiology of mutation carriers.  Therefore, it 
is important to identify additional BRAT targets and cellular processes important in OC initiation 
and progression.  While family history, usually associated with BRCA1 mutations, remains the 
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greatest risk factor for OC, inflammation may play an important secondary role in development 
of disease. Preliminary microarray analysis (Table 1.2) showed increased IL-1β gene expression 
in human immortalized OSE transiently expressing exogenous BRAT (Johnson, Kruk, 
unpublished data) suggesting IL-1β as yet another target of BRAT. Therefore, the risk for OC by 
BRCA1 185delAG may be mediated, in part, by the ability of 185delAG/BRAT to promote an 
inflammatory phenotype. 
 
Central Hypothesis 
I hypothesize that expression of the 185delAG BRCA1 mutant protein product, BRAT, 
alters the regulation and expression of the proinflammatory cytokine, IL-1β; which, in turn, may 
be of clinical relevance.   
 
Specific Aims 
 To address this central hypothesis, I propose three specific aims. 
1. Confirm IL-1β as a downstream target of 185delAG in immortalized human OSE 
cells. 
2. Determine the clinical correlation of urinary IL-1β among gynecologic patients. 
3. Establish the tools to determine the mechanism by which BRAT mediates novel gain 
of function. 
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Table 1.2 Microarray Condensed Results Showing Gene Expression Change. 
Gene Change PCDNA3.1 vs BRAT Average fold change 
IL1α I 4.61 
IL1β I 3.84 
IL6 I 2.50 
MMP1 I 2.70 
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Chapter 2:  
 
BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface 
Epithelial Cells 
Introduction 
 Ovarian cancer (OC), an inflammation associated cancer, is the deadliest gynecologic 
malignancy and is the 9th most common cancer among women [1].  The American Cancer 
Society estimates that approximately 22,240 new cases will be diagnosed and 14,030 women die 
of the disease annually, respectively [1].  The 5-year survival rate is 92% when diagnosed in 
early stage and yet confined to the ovary [1].  However, only about 15% of cases are diagnosed 
in the early stage and the 5-year survival rate drops to approximately 27% when diagnosed in 
later stages [1]. 
 Most OCs are epithelial ovarian carcinomas traditionally thought to arise from the 
ovarian surface epithelium (OSE) [2]; though more recently, studies have suggested that OC may 
arise from the fallopian tube epithelium [3, 4].  The etiology of the disease is not completely 
understood, but family history (FH) is the strongest risk factor for the development of epithelial 
OC [5].  Hereditary OCs are often associated with mutation of the tumor suppressor breast 
cancer susceptibility gene 1 (BRCA1) [6].  Carriers of the BRCA1 mutation have a 30% risk of 
developing OC during their lifetime [7].  BRCA1 plays a role in DNA damage response, cell 
cycle signaling, recruitment of chromatin modifying proteins, interaction with transcription 
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factors, and ubiquitin ligase activity [8].  Loss of these functions may contribute to the 
development of cancer by promoting genomic instability and accumulation of cancer-causing 
mutations.  Mutation of the BRCA1 gene can result in either “loss of function” or “gain of 
function” with appearance of novel truncated protein products, respectively (reviewed in [9]).  
Among possible gain of function BRCA1 mutations, the 185delAG mutation is one of the most 
common founder mutations and is associated with a 66% lifetime risk of developing OC [10]. 
 The 185delAG BRCA1 truncated mutant, BRAT, is a result of a deletion of two 
nucleotides in the second exon of the BRCA1 gene leading to a reading frame shift and a 
premature stop codon at exon 39.  Previously, we have demonstrated that human OSE cells with 
the BRAT mutation exhibited enhanced apoptosis and caspase-3 activation in response to 
stauosporine [11] as well as diminished levels of phosphorylated Akt, cellular inhibitor of 
apoptosis 1 (cIAP1), and X-linked inhibitor of apoptosis protein (XIAP) [12].  We have also 
found that BRAT up-regulated maspin expression was correlated with enhanced 
chemosensitivity [13] which is in agreement with clinical reports of increased survival in patients 
with elevated maspin levels [14]. Microscopic examination of ovarian specimens obtained 
following prophylactic oophorectomy from women with family history (FH) of OC indicated 
that greater than 85% presented with two or more abnormal OSE histologic features such as 
surface epithelial pseudostratification, surface papillomatosis, cortical invaginations of OSE 
epithelial inclusion cysts and epithelial hyperplasia [15]. Likewise, overtly normal FHOSE in 
culture show an increased autonomy of the epithelial phenotype in terms of expression of the 
epithelial differentiation marker CA125 [16], persistence of an epithelial morphology  [16], and a 
reduction in epithelial-mesenchymal conversion as noted by the maintenance of high keratin 
expression, but reduction of collagen type II expression compared with no family history (NFH) 
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OSE [17]. Since OSE become more firmly committed to an epithelial phonotype in the course of 
carcinogenesis, these reports coupled with our previous findings suggest that pre-neoplastic 
characteristics may already exist in overtly normal OSE in some women with a strong family 
history of breast and OC. 
Inflammation of the ovarian epithelium has long been associated with increased risk for 
OC [18-21].  By promoting a local pelvic inflammatory reaction, endometriosis has been 
associated with increased risk for endometrioid adenocarcinoma and clear cell carcinoma of the 
ovary [22-25]. Likewise, chronic pelvic inflammatory disease, often resulting from infection, 
also supports a role for inflammation and increased risk for OC [26, 27]. Lastly, epidemiological 
studies suggest that incessant ovulation causes rapid cycles of OSE division associated with 
repeated ovulatory traumatization and repair of the ovulatory defect [28]. Ultrastructural and 
histochemical studies of OSE in situ have shown that OSE migrates and proliferates extensively 
during repair of the OSE after ovulation [29, 30].  During the ovulatory repair, the OSE is 
exposed to proinflammatory mediators such as, cytokines, chemokines, matrix-remodeling 
enzymes, and various growth factors that can result in an increased risk of malignant 
transformation ([31, 32]).  Reports of OC associated with ovarian hyperstimulation due to 
fertility drugs [33, 34] further support a role for inflammatory traumatization in OC.  
Interleukin-1β (IL-1β) is a proinflammatory cytokine mainly produced by monocytes and 
macrophages [35], but can also be produced by endothelial cells, fibroblasts, and epidermal cells 
in response to bacterial or innate immunity stimulation [36].  Interestingly, normal and malignant 
epithelial ovarian cells also produce IL-1β [2].  IL-1β is translated into a 31kDa inactive 
precursor form that is cleaved intracellularly by caspase-1 into an active 17kDa secreted form 
[35].  The aim of this study was to investigate the in vitro production of IL-1β in human OSE 
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cell lines carrying the 185delAG BRCA1 mutation in order to determine whether enhanced IL-
1β in these cells could contribute to an inflammatory phenotype. 
 
Materials and Methods 
Cell Culture and Transfection 
The following SV 40-Large T-Antigen transfected human OSE (IOSE) cell lines were 
used: IOSE118 derived from a normal patient with a family history (FH) of breast and/or OC 
with wtBRCA1 status confirmed [13]; IOSE 121 derived from a normal patient with no family 
history (NFH) of breast and/or OC though BRCA1 mutation status was not determined and; 
IOSE 3261-77 and IOSE 1816-686 derived from normal patients with a FH of breast and/or OC 
as well as confirmed carriers of the BRCA1 185delAG mutation.  IOSE cells were cultured in 
Medium 199/MCDB 105 (Sigma, St. Louis, MO) with 10% fetal bovine serum (FBS) and 
gentamicin.  Multiple stable BRAT clones were generated by transfection of 2.5 x 105 IOSE 118 
cells with 2.5ug of PCDNA3.1 or Flag-BRAT with G418 resistance gene as previously described 
[13] using Program X-005, Kit V, and the Nucleofector device (Amaxa/ Lonza, Walkersville, 
MD).  BRAT clones were designated BRATc1, BRATc2, BRATc3, and BRATc4.  Stable cells 
were maintained in 1mg/ml G418 selection media and confirmed to express BRAT by RT-PCR 
[13].  All cells were incubated at 37°C with 5% CO2.  For knockdown studies, cells were co-
transfected with 1.5ug ON-Targetplus siRNA (SiCreb, SiCon) from Dharmacon (Chicago, IL).  
For treatment with IL-1 Receptor antagonist (IL-1Ra), stable BRAT clones were washed with 
phosphate buffered saline (PBS) and media containing 0.1% FBS was added to the cells along 
with varying concentrations of IL-1Ra (R&D Systems, Inc., Minneapolis, MN).  After 6 hours, 
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the media was removed and RNA was extracted from the cells for PCR analysis as described 
below. 
MCF7, SkBr3, and MDA-MB-231 human breast cancer cells were cultured in Medium 
199/MCDB 105 with 10% FBS and gentamicin.  MCF10A normal human breast epithelial cells 
were cultured in DMEM/F12 (Mediatech, Manassas, VA) supplemented with 15mM HEPES, 
insulin 10ug/mL, EGF 20ng/mL (Sigma, St. Louis, MO), choleratoxin 100ng/mL (Biomol, 
Plymouth Meeting, PA), hydrocortisone 0.5ug/mL (BD Biosciences, Sparks, MD), L-glutamine 
(MP Biomedicals, Solon, OH), glucose, sodium bicarbonate, 10% FBS, and gentamicin.  All 
cells were incubated at 37°C with 5% CO2.  Two million cells were transiently transfected with 
BRAT as previously described [13] using Program X-005 (for MCF7 cells), E-09 (for SkBr3 
cells), X-013 (for MDA-MB-231 cells), T-024 (for MCF10A cells), Kit V, and the Nucleofector 
device (Amaxa/ Lonza, Walkersville, MD) with 2.5-3.5ug of plasmid (pcDNA3.1 or Flag-
BRAT). 
Western blot 
Cells were washed in PBS, trypsinized, pelleted, and washed 1-2 times in cold PBS.  
Cells were lysed for 30 minutes on ice in modified CHAPS buffer, and lysate was centrifuged at 
115,000 x g, at 4°C for 1h.  Then 30ug of protein were separated via 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE).  Proteins were transferred to Polyvinylidene 
fluoride (PVDF) membranes, dried, and blocked in 5% milk in Tween 20-Tris buffered Saline.  
Blots were incubated in their respective antibodies overnight, followed by incubation with a 
horseradish peroxidase (HRP)-conjugated secondary (Fisher, Pittsburgh, PA), and developed via 
enhanced chemiluminescence substrate (ECL) (Pierce/ Fisher, Pittsburgh, PA).  Antibodies: IL-
1β (1:1000) Cat. # 2022 Cell Signaling Technology (Beverly, MA), Actin clone AC-40 
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(1:10,000) Cat. # 4700 Sigma (St. Louis, MO), Apoptosis-associated Speck-like protein 
containing a C-terminal caspase recruitment domain (ASC) (1:1000) Cat. # sc-271054 Santa 
Cruz Biotechnology, Inc. (Dallas, TX), Caspase-1(1:1000) Cat. # 2225 Cell Signaling 
Technology (Beverly, MA), CREB (1:1000) Cat. # 9104 Cell Signaling Technology (Beverly, 
MA), NACHT, LRR and PYD domains-containing protein 3 (NALP3) (1:1000) Cat. # sc-
134306 Santa Cruz Biotechnology, Inc. (Dallas, TX).  Western blot quantification was done in 
ImageJ software normalizing band strength to the actin band. 
Enzyme-linked Immunosorbent Assay 
For conditioned media analysis, media containing 0.1% FBS was added to cells 24 hours 
after transfection/ plating.  After 24 hours, cells were counted and media was collected and 
centrifuged to remove debris, aliquoted, and stored at (-80°C).  For the IL-1β Enzyme Linked 
Immunosorbent Assay (ELISA), conditioned media was also concentrated 17x using Amicon 
Ultra-15 Centrifugal Filter Unit with Ultracel-10 membrane (Millipore, Billerica, Massachusetts) 
before storage at (-80°C).  To assess the presence of mature IL-1β, an ELISA (R&D Systems, 
Inc., Minneapolis, MN) was performed on concentrated conditioned media samples in triplicate 
according to manufacturer’s protocol.  Fluorescence was read on an ELx800 Absorbance 
Microplate Reader (Biotek, Winooski, Vermont) using Gen5 Data Analysis Software (Biotek, 
Winooski, Vermont).  Resultant values were derived from a standard curve and expressed as the 
mean IL-1β concentration of triplicate samples ± standard error.  When cell viability varied 
significantly, IL-1β concentration was normalized to average cell number at time of conditioned 
media collection.  
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PCR 
RNA samples were isolated using TRIzol reagent from Invitrogen (Carlsbad, CA) per 
manufacturer’s protocol and DNAse treated.  
For BRAT semi-quantitative PCR to confirm transfection, 1ug total RNA, oligo(dT), and 
reverse transcriptase were used to generate single-strand cDNA as previously described [13].  
The cDNA samples were amplified using the Applied Biosystems GeneAmp RNA PCR Core Kit 
(Foster City, CA). Primers used were: Flag-BRAT sense 
(CGATGACAAAATGGATTTATCTGC), Flag-BRAT antisense 
(GAGACAGGTTCCTTCATCAACTCC), actin sense 
(GGGAATTCAAAACTGGAACGGTGAAGG), and actin antisense 
(GGAAGCTTATCAAAGTCCTCGGCCACA). The amplified products were separated by 
electrophoresis on a 10% polyacrylamide gel, stained with SYBR Green (Lonza, Rockland, ME), 
and photographed with the Kodak EDS 120 Digital Analysis System. The net intensity of each 
band was normalized to the respective endogenous control band. 
For quantitative PCR, 100ng total RNA was reverse transcribed to generate single-strand 
cDNA as previously described [13].  The cDNA samples were amplified in triplicate using Fast 
SYBR Green Master Mix (Applied Biosystems) on an Applied Biosystems Step One Plus 
instrument.  Primers used were: IL-1β sense (TCCAGGGACAGGATATGGAG), IL-1β 
antisense (TCTTTCAACACGCAGGACAG), and actin (same as above).  RQ (relative mean 
mRNA expression level) was calculated by the Step One software version 2.0.  Using standard 
curves constructed for target and endogenous control genes, an arbitrary quantitative gene 
expression value was determined from the threshold cycle (Ct) for each gene for each sample.  
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Target gene values were normalized to control gene values, and fold difference was determined 
by dividing by the designated reference/ calibrator sample.  
Dual-Luciferase assay 
Stable 118 PCDNA3.1 or BRAT clones were transfected with 0.15ug Renilla luciferase 
reporter and 1.5ug IL-1β luciferase promoter deletion constructs pIL1(4.0kb)LUC (-4000), 
pIL1(3.1kb)LUC (-3100), pIL1(1.8kb)LUC (-1800), pIL1(0.9kb)LUC (-900), and 
pIL1(0.5kb)LUC (-500).  Twenty-four hours later, cells were collected in Promega Passive Lysis 
Buffer and subjected to two freeze-thaw cycles.  Lysates were centrifuged at 10,600 x g for 1 
minute at 4°C, and supernatant was collected.  Luciferase activity was assessed in triplicate using 
a manual luminometer and the Promega Dual Luciferase Assay System according to 
manufacturer protocol.  For knockdown reporter studies, siRNA was co-transfected and cells 
were collected 48 hours after transfection.  
Immunoprecipitation 
Cells from stable 118 PCDNA3.1 and BRAT clones were washed with PBS incubated on 
ice with RIPA buffer containing protease inhibitors.  After 15 minutes, the cells were removed 
by scraper and lysate was incubated for 60 minutes on ice.  The cell suspension was centrifuged 
at 10,000 x g for 10 minutes at 4°C.  Two micrograms of primary antibody was incubated with 
1mg of whole cell lysate for 2 hours at 4°C.  Protein A/G agarose suspension was added to lysate 
and antibody mixture followed by incubation at 4°C on a rocker overnight.  The suspension was 
collected by centrifugation at 500 x g for 2 minutes at 4°C.  The cell pellet was washed with 
RIPA buffer containing protease inhibitors followed by analysis by western blot. 
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Statistics 
For real time PCR, error bars illustrate RQmin and RQmax, which are calculated as:  
RQave divided by (standard deviation^ student’s t value at the 95% confidence interval, for 5 
degrees freedom) and RQave times (standard deviation^ student’s t value at the 95% confidence 
interval, for 5 degrees of freedom), respectively.  This range represents the confidence interval at 
the 95% confidence level.  For ELISA and reporter assay data, student’s t test was performed to 
assess statistical difference between means of triplicates ± standard error from three separate 
experiments.  
 
Results 
IL-1β levels are increased in IOSE cells carrying BRCA1 185delAG mutation. 
To determine the relationship between the BRCA1 185delAG mutation and the protein 
levels of IL-1β, I compared IL-1β protein levels in human OSE cell lines that endogenously 
carry this mutation to those with wild-type BRCA1 mutation.  Both FH IOSE cell lines (3261-77 
and 1816-686) with confirmed 185delAG mutation had at least 7-fold higher pro-IL-1β protein 
levels as well as ≥ 13-fold higher active IL-1β protein levels as measured by western blot than 
the NFH cell line (IOSE-121) (Figure 2.1A).  I further examined secreted IL-1β protein levels in 
these same cell lines.  The 3261-77 and 1816-686 cell lines had 2- and 10-fold, respectively, 
higher levels of secreted IL-1β protein in their conditioned media as measured by ELISA than 
the IOSE-121 cell line (Figure 2.1B). 
BRAT transfection increases levels of IL-1β in IOSE cells. 
To confirm that the increased intracellular and secreted IL-1β levels are related to the 
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A. 
  
B. 
 
Figure 2.1. IL-1β protein levels are increased in 185delAG BRCA1 mutation carriers.  (A) 
Normal IOSE cells were analyzed for precursor (pro-) and cleaved IL-1β protein expression via 
western blot.  Blots were then stripped and probed for β-actin as a loading control.  Values 
represent relative densitometry.  (B) Cells were plated in triplicate at similar densities and 
conditioned media was collected as described.  IL-1β ELISA activity assay was performed in 
triplicate as described.  Graph illustrates mean ± standard error.  Symbol (*) denotes statistical 
significance at the 0.04 confidence level.   
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presence of BRAT, I analyzed IOSE-118 cells stably transfected with PCDNA3.1 or Flag-BRAT 
for IL-1β protein levels. BRATc1 had 2.7-fold higher levels of intracellular IL-1β protein as 
measured by western blot than the PCDNA3.1 cell line (Figure 2.2A).  Furthermore, BRATc1 
and BRATc2 both had 2-fold and 1.5-fold, respectively, higher levels of secreted IL-1β protein 
levels as measured by ELISA than the PCDNA3.1 cell line (Figure 2.2B). To determine whether 
BRAT-mediated IL-1β expression is transcriptionally regulated, I evaluated IL1β mRNA level in 
BRAT-expressing IOSE-118 cells.  Stably transfected IOSE-118 BRAT cells showed up to a 3-
fold increase in IL1β mRNA expression as measured by real time PCR, compared to PCDNA3.1 
cells (Figure 2.2C).   
BRAT-mediated IL1β expression is tissue specific. 
To determine whether BRAT-mediated enhanced IL1β mRNA levels is specific to 
ovarian epithelial cells, normal breast epithelial (MCF-10A) and breast cancer (MDA-MB-231, 
SK-BR-3, and MCF-7) cell lines were transiently transfected with PCDNA3.1 or BRAT 
transcript.  Real time PCR of the breast cell lines showed no change in IL1β mRNA in the 
PCDNA3.1 and the BRAT transfected cell lines (Figure 2.3).  
BRAT-mediated IL1β promoter activity is partially mediated by CREB in IOSE cells. 
To determine which region of the IL1β promoter was required for the BRAT-mediated 
IL1β promoter activation, I utilized dual-reporter assays in BRAT cells using five truncated IL1β 
promoter luciferase reporter plasmids.  There was no difference in reporter activity between 
deletion constructs (-4000), (-3100), and (-1800) (Figure 2.4A).  However, reporter activity was 
diminished by 80% between deletion constructs (-1800) and (-900) (Figure 2.4A).  Furthermore, 
there was no difference in reporter activity between deletion constructs (-900) and (-500) (Figure 
4A).  
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A.       B. 
 
C.  
 
Figure 2.2. IL-1β protein and message levels are increased in stably transfected 185delAG 
OSE cells.  (A) IOSE 118 cells were transfected with pcDNA3.1 (control) or 185delAG 
transcript (BRATc1) and subsequently analyzed for precursor (pro-) and cleaved IL-1β protein 
expression via western blot. Blots were then stripped and probed for β-actin as a loading control.  
Values represent relative densitometry.  (B) pcDNA3.1, BRATc1, and BRATc2 cells were plated 
in triplicate at similar densities and conditioned media was collected as described.  IL-1β ELISA 
activity assay was performed in triplicate as described.  Graph illustrates mean ± standard error.  
Symbol (*) denotes statistical significance at the 0.01 confidence level between BRAT and 
PCDNA3.1 cells. (C). Cells stably expressing BRAT or the pcDNA3.1 cells were plated at equal 
densities and collected.  RNA was isolated, DNAse treated, and reverse transcribed.  Real-time 
PCR was performed in triplicate for IL-1β and actin using SYBR green detection.  Graph 
illustrates mean ± standard error. 
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Figure 2.3. BRAT-mediated IL-1β expression is tissue specific. MCF-10A (normal breast 
epithelial), SK-BR-3 (breast cancer), and MCF-7 (breast cancer) cells were plated at equal 
densities, transiently transfected with either BRAT or the pcDNA3.1 vector, and RNA was 
collected 48 hours after transfection.  RNA was isolated, DNAse treated, and reverse transcribed.  
Real-time PCR was performed in triplicate for IL-1β and actin using SYBR green detection.  
Graph illustrates mean ± standard error. 
 
  
Normal breast 
epithelial 
Breast cancer 
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A. 
 
B. 
 
Figure 2.4. CREB sites within the IL-1β promoter mediate enhanced IL-1β mRNA 
expression in BRAT cells.  (A) Cells stably expressing BRAT were transiently transfected with 
the indicated IL-1β deletion reporter construct and a Renilla constitutive luciferase reporter 
plasmid for normalization.  Lysates were collected, subjected to two freeze-thaw cycles, and 
assayed in triplicate on a manual luminometer using Promega’s Dual Luciferase Assay kit.  
Luciferase activity was normalized to Renilla luciferase activity for each triplicate, averaged, and 
results are expressed as mean ± standard error.  (B) Cells stably expressing BRAT were also co-
transfected with non-targeting control siRNA (siCon) or siRNA targeting CREB, collected, and 
assayed similarly.  Protein lysates were collected in parallel for knockdown analysis and CREB 
protein silencing demonstrated by western blot (inset). Symbol (*) denotes statistical significance 
≤ 0.03 confidence level. 
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This suggests that the 900bp region between the (-1800) construct and the (-900) construct 
contributes significantly to BRAT-mediated IL1β promoter activity. 
To further evaluate BRAT-mediated IL1β promoter activation, I performed an online 
transcription factor prediction analysis of the 900bp promoter region identified earlier to 
determine potential transcription factor binding sites using the prediction software, PROMO [37, 
38].  My analysis identified two potential CREB binding sites within the 900bp promoter region.  
Based on this observation, I used pooled siRNA to knockdown CREB and western blot to 
confirm CREB silencing.  I then analyzed IL1β promoter activity using the (-1800) reporter 
plasmid.  Knockdown of CREB resulted in partial loss of reporter activity (Figure 2.4B).  This 
data suggests that CREB is at least partially required for activation of the IL1β promoter in 
BRAT cells. 
Caspase-1 protein expression is increased in BRAT IOSE cells. 
To confirm the intracellular processing of precursor inactive IL-1β into its active form, I 
measured caspase-1 levels, the known intracellular activator of IL-1β.  Stably transfected 
PCDNA3.1 cells had about 2-fold more inactive precursor caspase-1 protein levels than BRAT 
cells as seen by western blot (Figure 2.5).  However, stably transfected BRAT cells showed up to 
a 50-fold increase in active caspase-1 as seen by western blot (Figure 2.5).  
ASC protein expression is increased in BRAT IOSE cells. 
BRAT increases precursor IL-1β protein by increased transcription and concurrently 
increases active caspase-1 by unknown mechanisms to accommodate cleavage of precursor IL-
1β to active IL-1β.  To determine the control of enhanced activation of caspase-1 by the NALP3-
ASC inflammasome in BRAT cells, the presence of NALP3 and ASC were determined by Co-IP 
and visualized by western blot.    
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Figure 2.5. Cleaved caspase-1 is elevated in BRAT cells.  Cells stably expressing pcDNA3.1 
or BRAT (BRATc1 & BRATc2) were analyzed for precursor (pro-caspase-1) and cleaved 
caspase-1 (caspase-1 p20) protein expression via western blot.  Blots were then stripped and 
probed for β-actin as a loading control.  Values represent relative densitometry.   
 
Stably transfected PCDNA3.1 and BRAT cells were immunoprecipitated with an ASC 
antibody, followed with a western blot probed for NALP3 and ASC.  PCDNA3.1 and BRAT 
cells showed similar protein levels of NALP3; however, BRAT cells showed an increase in ASC 
protein levels (Figure 2.6A).  Additional western immunoblots confirmed a 2.5 fold increase of 
ASC protein levels in BRAT cells compared to the PCDNA3.1 cells (Figure 2.6B).  
IL-1Ra suppresses proinflammatory mediators in BRAT IOSE cells. 
To evaluate the potential auto-feedback loop of IL-1β on OSE cells, I treated stably 
transfected BRAT-containing IOSE cells with the IL-1 receptor antagonist, IL-1Ra. Then, I 
measured mRNA expression levels of known IL-1β downstream transcription targets: IL-1β, IL-
6, and IL-8 by real time PCR.  Treatment of BRAT cells with IL-1Ra resulted in about a 50% 
loss of mRNA expression levels of IL-1β, IL-6, and IL-8, respectively, at the 0.5ng/mL treatment 
level (Figure 2.7).  
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A.  
 
B. 
 
Figure 2.6. BRAT alters levels of inflammasome constituents.  (A) Cells stably expressing 
pcDNA3.1 or BRATc4 were immunoprecipitated with the ASC antibody, then analyzed via 
western blot for ASC and NALP3.  Values represent densitometry.  (B) Cells stably expressing 
pcDNA3.1 or BRAT were analyzed for ASC protein expression via western blot.  Blots were 
then stripped and probed for β-actin as a loading control.  Values represent relative densitometry.   
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Figure 2.7. IL-1Ra inhibits IL-1β, IL-6, and IL-8 mRNA expression in BRAT cells.  Cells 
stably expressing BRAT were plated at equal densities, treated with recombinant IL-1Ra and 
collected.  RNA was isolated, DNAse treated, and reverse transcribed.  Real-time PCR was 
performed in triplicate from two separate experiments for IL-1β, IL-6, IL-8, and actin using 
SYBR green detection.  Graph illustrates mean ± standard error. 
 
 
Discussion 
The results of the present study show that the 185delAG BRCA1 mutant protein, BRAT, 
increases IL-1β mRNA and protein levels in immortalized human OSE cell lines.  Furthermore, I 
have demonstrated that BRAT-dependent expression is transcriptionally mediated, in part, via 
CREB binding sites.  I have also demonstrated that BRAT-dependent activation of IL-1β protein 
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by caspase-1 may be enhanced by increased ASC protein expression of the NALP3-ASC 
inflammasome.  While further investigation is required to discover the exact mechanism of 
enhanced ASC protein expression in BRAT cells, I suspect ASC expression may be CREB-
dependent or AP1-dependent since the current and prior studies indicate BRAT-mediated gene 
expression through CREB and AP1 sites [39] and CREB binding sites are potentially present in 
the ASC promoter according to commercially available promoter ChIP assay (Qiagen, Valencia, 
CA) program analysis.  Lastly, I have shown that IL-1β plays a role in the induced expression of 
proinflammatory mediators, IL-6 and IL-8 via the IL-1 receptor suggesting that BRAT might 
stimulate a proinflammatory environment that could promote OC oncogenesis. 
Establishing animal and cell models of OC oncogenesis has proven to be difficult.  
Spontaneous development of OC in animal models occurs with a low frequency and highly 
variable phenotype [40].  Furthermore, OC lacks a clear molecular profile making it difficult to 
elucidate a universal cause in OC initiation or progression [41-43].  Loss of some or all wild type 
functions of the BRCA1 gene product due to gene mutation is commonly associated with 
enhanced breast cancer and OC risk (Reviewed in [9]).  BRCA1 gene mutations resulting in a 
premature stop codon are generally susceptible to nonsense-mediated messenger RNA (mRNA) 
decay.  However, two common risk-associated BRCA1 mutations, 185delAG and 5382InsC, 
were found to be unaffected by mRNA decay [44, 45].  This study utilizes a stable OSE cell line 
model with intact endogenous bi-allele BRCA1 along with the 185delAG BRCA1 mutant 
transcript.  By retaining intact BRCA1, I am able to conclude the changes observed are due to 
the presence of the 185delAG BRCA1 mutation and not due to the partial or complete loss of 
BRCA1.  This is in keeping with previous studies that have shown other BRCA1 mutations with 
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independent and novel gain-of-function roles in OC proliferation, chemosensitivity, 
tumorigenesis, and apoptosis [46, 47].     
Mutation of the BRCA1 gene is associated with the majority of hereditary OCs resulting 
in a 30% lifetime risk of developing OC [7].  BRCA1 gene mutations are also associated with 50-
80% risk of developing breast cancer before 70 years of age [48].  The propensity for gender- 
and tissue-specific BRCA1+ disease has long been thought to be associated with estrogen in 
these hormone-responsive tissues [49] such that aberrations in the regulation and signaling 
interactions between BRCA1 and estrogen [50-53] promote breast and/or OC. Similar tissue 
specific disease development associated with gene mutations is not uncommon.  For instance, 
germline mutation of the ALK gene is associated with familial neuroblastoma, but can also be 
associated with lymphoma and lung cancer depending on the genetic aberration that occurs [54].  
However, not all BRCA1 germline carriers develop disease and carriers of a mutation rarely 
develop both ovarian and breast cancer.  A recent study by Maxwell et al. indicated that 
combined mutations in RHAMM secondary to BRCA1 mutations promoted Aurora kinase A- 
and TPX2-mediated disorganization of epithelial polarity, thereby potentiating breast 
carcinogenesis [55]. Similarly, I may have not noted changes in IL1β expression in breast tissue 
with the 185delAG plasmid because of the necessity of further genetic alterations needed to 
initiate breast cancer transformation.  Interestingly, the IOSE cells employed in this study 
overexpress p53 [56] as a result of nuclear sequestration by the large-T antigen which interferes 
with the growth regulatory activities of p53 [57] and which might mimic the high-grade, ‘type II’ 
pathway for OC development arising from p53 mutations [58]. However, given the range of p53 
status from wild-type to mutated/overexpressed to mutated/deficient among the breast cancer cell 
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lines [59-62] employed in this study, perhaps additional, genetic alterations unique to OSE limit 
BRAT-mediated IL-1β overexpression to the ovary. 
Inflammation has long been suggested to contribute to tumor initiation, promotion, and 
progression [63].  Many components of the inflammatory pathway, including free radicals, 
cytokines, cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and vascular 
endothelial growth factor (VEGF) have been implicated in the development of various 
malignancies, including OC [64].  Immunohistochemical analyses revealed increased COX-2 
expression in non-mucinous ovarian tumors and with increased COX-2 expression correlating 
with poor prognosis [65].  Likewise, the present results are in keeping with others who reported a 
relation between proinflammatory mediators and increased OC risk.  A case-control study 
confirmed a positive association between circulatory inflammatory cytokines, IL-2, IL-4, IL-6, 
IL-12, and IL-13, and OC risk [66].  Also, increased serum levels of inflammatory marker CRP 
were associated with an increased risk of OC [20, 67]. Yellapa et al., demonstrated increased 
expression of the proinflammatory cytokine, IL-16, in serum and tissue of early and late stage 
OC patients; as well as, increasing IL-16 serum levels during the progression from normal to 
early and late stage OC progression in hens [68].  Further, since increasing IL-16 serum levels 
preceded detection of OC by transvaginal ultrasound, it is tempting to speculate that monitoring 
proinflammatory mediators, such as IL-1β, may signal disease in women at high risk for OC 
before detection by conventional means.  
In contrast, epidemiological studies suggest that long-term usage of non-steroidal anti-
inflammatory drugs (NSAIDs) is associated with decreased OC risk [69-71].  Further, in vitro 
and in vivo use of phytochemicals [72] exert anti-inflammatory activity related to reduced OC 
progression by stabilizing p53 [73], enhancing cisplatin sensitivity  [74], inhibiting cell growth 
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and VEGF expression [75] and suppressing IL-6 function [76].  There are currently three IL-1 
inhibitors used in the treatment of non-malignant inflammatory conditions: recombinant IL-1Ra, 
anakinra; IL-1 trap, rilonacept; and monoclonal anti-IL-1β antibody, canakinumab [77].  
Consequently, premalignant targeting of the proinflammatory mediator IL-1β and its upstream 
processors, caspase-1 and/or the NALP3 inflammasome, specifically in 185delAG BRCA1 
mutation carriers, may reduce the risk of malignant transformation initiated by chronic 
inflammation.   
Lastly, tumors can develop within and in response to their inflammatory 
microenvironment. For example, Kim et al., observed localized IL-1 expression among normal, 
benign, and malignant canine mammary tumors such that IL-1 could not be detected in normal 
tissue while concentrated IL-1 expression was noted in the stroma of benign tumors and diffused 
expression in malignant and metastatic tumors [78].  Similarly, IL-1β secreted by OC cells 
suppresses p53 expression in cancer-associated fibroblasts [79]. In OC, IL-1β also promotes 
invasiveness, tumor angiogenesis, and induces immune suppression [80].  Constitutive 
production of IL-1β by human ovarian carcinoma cell lines [81] enhances their invasion 
capacities by increasing expression of matrix metalloproteinase-1 and stimulating production of 
pro-angiogenic factors [82, 83].  Watanabe, et al. showed that IL-1β produced by OC cells 
induced mesothelial cell beta1-integrin dependent peritoneal metastasis [84].  Increased levels of 
IL-1β found in the serum and/or the ascites of OC patients was associated with decreased 
survival [85].  Likewise, IL-1β can affect OC progression by altering the expression of other 
proinflammatory cytokines, such as IL-6 which is a downstream target of IL-1β.  IL-6 is known 
to play a major role in OC progression and prognosis; and may also be a potential marker of 
immunological and metabolic changes in OC [86].  Elevated levels of IL-6 was found in the 
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serum and ascites of OC patients [87]; and was also associated with poor prognosis [2].  
Therefore, the chronic presence of IL-1β within the ovarian microenvironment may enhance 
malignant transformation and underscores the complexity among cancer cells within their 
microenvironment for tumor progression.  
The data identify the proinflammatory mediator, IL-1β, as a novel target in OSE cells 
expressing the 185delAG BRCA1 mutation.  Further, the mechanism by which BRAT regulates 
IL-1β expression is twofold: (1) CREB-dependent transcriptional control and (2) caspase-1 
protein cleavage of IL-1β. Further studies on the role of BRCA1 mutations to promote a chronic 
inflammatory phenotype are warranted since the potential exists for IL-1β to serve as a predictor 
of OC and/or as a therapeutic target. 
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Chapter 3: 
 
Urinary Interleukin-1β Levels Among Gynecological Patients 
 
Introduction 
Ovarian cancer (OC) is the fifth leading cause of cancer death among women after lung, 
breast, colorectal, and pancreatic cancer [1].  OC is highly treatable when diagnosed in the early 
stages; however, the majority of cases are diagnosed in the late stage and 5-year survival is 
approximately 27% [1]. 
In order to detect early stages of OC and avoid unnecessary surgery, there is a need for a 
better understanding of the etiology of this disease as well as improved screening options.  
Currently, there are three screening procedures in use for OC detection: bimanual pelvic 
examination, serum CA125, and transvaginal ultrasonography (TVS) [2].  Pelvic examinations 
are not effective in distinguishing a premalignant lesion from a normal ovary [3].  Serum CA125 
is elevated in 47% of women with early stage OC and elevated in 80-90% of advanced stage 
OCs [4].  However, CA125 can also be elevated in healthy women and in patients with benign 
ovarian disease [5]; as well as, in other cancers such as endometrial, pancreatic, lung, breast, 
colorectal, and certain gastrointestinal tumors [6].  The pairing of TVS with serum CA125 
improves OC diagnosis; however, sonography can result in false positive results and unnecessary 
surgery [7].  Unfortunately, utilizing these methods either alone or in combination does not 
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produce the desired results for early disease detection.  Therefore, examining the molecular 
changes that occur at early disease onset may provide new approaches or biomarkers for OC 
detection. 
Deregulation of inflammation due to overexpression of proinflammatory proteins 
contributes to the malignant phenotype by supporting cancer cell growth and tumor invasion.  
Since the proinflammatory cytokine, interleukin-1β (IL-1β), is: constitutively expressed in OC 
[8] elevated in serum of OC patients [9]; expressed in cultured OC and FH IOSE cells (chapter 
2) and; secreted by ovarian cells (chapter 2), I sought to assess whether elevated urinary levels of 
IL-1β are associated with OC as well as compare urinary IL-1β levels with clinical parameters. 
 
Materials and methods 
Patient cohort 
 With prior institutional approval, urine samples were collected from an initial cohort of 
healthy controls (N=7), women with ovarian benign disorders (N=12), and patients with 
epithelial OC (N=20) at the H. Lee Moffitt Cancer Center at the University of South Florida 
(MCC/USF).  Table 3.1 shows an age match subset developed from OC patients in the 
MCC/USF cohort to produce a patient group with an age range (26-92 years and 26-75 age 
match) more similar to healthy control (37-60 years) and ovarian benign disease (28-81) groups, 
respectively.  The OC category consisted of women diagnosed with OC and primary peritoneal 
cancer, which is often related to OC.  The samples collected from women with ovarian benign 
disease consisted of broad range of non-malignant gynecologic disorders.  The second urine 
cohort collected with IRB approval at Tampa General Hospital (TGH) consisted of healthy 
controls (N=3), women with ovarian benign disease (N=11), women with epithelial OC (N=12), 
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women with other benign gynecologic disease (N=22), and other gynecologic cancers (N=6).  
Though these cohorts comprise a small pilot study (Table 3.1), they are representative of a 
typical clinical practice with regards to histology subtypes.   
Where possible, H & E sections from paraffin blocks were reviewed to confirm the 
histologic diagnosis according to FIGO scores.  Anonymized information regarding patient age, 
body mass index (BMI), and tumor type were also obtained as per availability. 
Sample Preparation 
Urine samples were collected from patients, anonymized to protect patient identity, and 
released from the tissue banks for this research project.  All samples were kept in ice following 
collection.  MCC/USF urine samples were treated with a standard protease inhibitor cocktail 
(80ug/mL 4-(2 aminoethyl)-benzene sulfonyl fluoride, 200ug/mL EDTA, 0.2ug/mL leupeptin, 
0.2ug/mL pepstatin, Sigma Scientific, St. Louis, MI).  All samples were centrifuged at 3000 × g.  
Urinary supernates and serum samples were then aliquoted and stored at -20°C.   
Enzyme-linked Immunosorbent assay 
 To measure IL-1β levels in patients’ urine and serum, samples were assayed using the 
quantitative sandwich enzyme-linked immunosorbent assay (ELISA; R&D Systems, Inc., 
Minneapolis, MN) according to the manufacturer’s instructions.  Fluorescence was read on an 
ELx800 Absorbance Microplate Reader (Biotek, Winooski, Vermont) using Gen5 Data Analysis 
Software (Biotek, Winooski, Vermont).  Resultant values were derived from a standard curve 
and expressed as the mean IL-1β concentration of triplicate samples ± standard error. 
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Statistical analysis 
Samples for IL-1β ELISA were run in triplicate and the data subjected to descriptive, one 
way ANOVA, parametric, Kruskal-Wallis, Mann-Whitney U, Spearman correlation, and 
Wilcoxin W analyses. 
 
Results 
Urinary levels of IL-1β decrease with increasing patient age. 
 Levels of urinary IL-1β were compared in 93 patients of the entire cohort and 87 patients 
of the age matched subset.  Average urinary IL-1β levels were compared to patient age and as 
divided by decade grouping.  The highest levels of urinary IL-1β were found in the 20-29 and 
30-39 age groups in both the entire cohort (Figure 3.1A) and the age matched subset (Figure 
3.1B), respectively, suggesting a relationship between increasing age and urinary IL-1β levels. 
 Levels of serum IL-1β were compared in 19 patients of the entire cohort.  In agreement 
with comparisons between urinary IL-1β levels with age, serum IL-1β levels showed a similar 
pattern with the highest average serum IL-1β level in the 20-29 age group (Figure 3.1C).  This 
further confirms a possible relationship between age and IL-1β levels.  Despite the tendency for 
increased urinary IL-1β levels in the 20-29 and 30-39 age groups, no statistical differences were 
found.  
Urinary IL-1β levels are elevated in patients with ovarian cancer. 
 The levels of urinary IL-1β were generally negligible (average 0.36 pg/ml) in healthy 
control samples of the entire cohort and the age match subset, respectively (Figure 3.2A & 3.2B).  
However, urinary levels from women with benign ovarian disease were increased approximately 
four-fold compared to healthy controls (average benign 1.26 pg/ml) (Figure 3.2A & 3.2B).    
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A. 
  
B. 
 
Figure 3.1.  Urinary and serum levels of IL-1β are elevated in 20-29 and 30-39 years age 
groups.   
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C. 
  
Figure 3.1 Continued.  Urinary and serum levels of IL-1β are elevated in 20-29 and 30-39 
years age groups.  ELISA was utilized to measure IL-1β (mean pg/ml) in the urine and serum of 
study samples.  (A) Urinary levels in all samples (N=92).  (B) Urinary levels in age match subset 
(N=86).  (C) Serum levels in available samples.  Samples were examined in triplicate and the 
data expressed as mean. 
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A. 
B.
 
Figure 3.2. Urinary IL-1β levels are elevated in ovarian cancer patients. 
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C. 
D.  
  
Figure 3.2 Continued. Urinary IL-1β levels are elevated in ovarian cancer patients. 
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Figure 3.2. Urinary IL-1β levels are elevated in ovarian cancer patients.  Urinary samples 
were analyzed in triplicate by ELISA and data expressed as mean ± standard error in pg/ml.  (A) 
Entire cohort of healthy controls, benign ovarian disorders, ovarian cancer patients, other 
gynecological benign disorders, and other gynecological cancers; (B) age match subset of 
healthy controls, benign ovarian disorders, ovarian cancer patients, other gynecological benign 
disorders, and other gynecological cancers.  (C) Non-inflammatory benign disorders and 
inflammatory benign disorders in all ovarian benign and other gynecological benign disorders.  
(D) Average age and average urinary IL-1β per diagnosis of healthy (normal) (N=10), benign 
ovarian disorder (N=25), and ovarian cancer (N=27).  Data expressed as mean ± standard 
deviation of age (in years).   
 
 
Likewise, urinary levels of IL-1β associated from OC patients exhibited the highest average 
levels of 1.57 pg/ml IL-1β in the entire cohort (Figure 3.2A) and 1.88 pg/ml IL-1β in the age 
matched subset (Figure 3.2B), respectively.  Levels of urinary IL-1β in other gynecological 
benign disorders (average 1.56 pg/ml) and other gynecological cancers (average 1.36 pg/ml) 
were increased in comparison to healthy controls (p ≤ 0.005 and 0.05), respectively, but were 
decreased in comparison to urinary levels of IL-1β  from OC patients (Figure 3.2A & 3.2B). 
Average levels of urinary IL-1β were compared in all benign disorder patient samples, 
including both ovarian benign and other gynecological benign disorder patient samples.  The 
average urinary IL-1β levels were increased in inflammatory benign disorders (1.88 pg/ml) when 
compared to non-inflammatory benign disorders (0.82 pg/ml) (p = 0.001) (Figure 3.2C).  Levels 
of corresponding urine and serum IL-1β were available from 19 patients of the entire cohort.  
Paired serum IL-1β showed a similar pattern of increased average levels in the benign ovarian 
and OC group, respectively, with the highest average levels in the OC group (Figure 3.3).  Since 
there was a significant correlation between serum and urinary IL-1β levels in ovarian benign 
disorders (r = 0.949, N = 4, p = 0.051) and in OCs (r = 0.724, N = 11, p = 0.012), and there was a 
very limited number of available serum samples, all remaining clinical comparisons were 
completed in urine samples only. 
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When urinary IL-1β levels were analyzed in the age matched cohort with respect to 
diagnosis and age, the average age in the healthy controls, benign ovarian disorders, and OC 
patients was 49.3, 52.2, and 57.7 years, respectively (Figure 3.2D).  The average urinary levels 
of IL-1β in these healthy controls, benign ovarian disorders, and OC patients was 0.36 pg/ml, 
1.30 pg/ml, and 1.88 pg/ml, respectively (Figure 3.2D) supporting a trend for increased urinary 
IL-1β levels with disease progression. 
 
 
 
Figure 3.3. Urinary and serum IL-1β levels are elevated in ovarian cancer patients.  Urinary 
and serum samples were analyzed in triplicate by ELISA and data expressed as mean ± standard 
error in pg/ml.  Serum and urinary IL-1β in healthy controls, benign ovarian disorders, and OC 
patients.   
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Urinary IL-1β levels are increased in patients with a family history of cancer. 
Using the age matched sample subset, urinary IL-1β levels were analyzed with respect to 
a family history of cancer though the BRCA1 status of these patients could not be confirmed.  
Average urinary IL-1β levels in a healthy control patient with no family history of cancer was 
higher (0.93 pg/ml) compared to healthy control patients with a family history of cancer (0.27 
pg/ml) (Figure 3.4A).  In a patient with benign ovarian disease and no family history of cancer, 
urinary IL-1β levels were 0.33 pg/ml; while average levels were 0.96 pg/ml in benign ovarian 
patients with a family history of cancer (Figure 3.4A). 
Though I could not identify the lack of family history of cancer in most of the OC 
patients, in those OC patients with confirmed family history of cancer average urinary IL-1β 
levels were 6.33 pg/ml (Figure 3.4A), while the average urinary IL-1β levels of the remaining 
OC patients was 1.16 pg/ml.  However, when sample 3119-13 that is about 20-fold higher than 
the other similar samples was excluded from the analyses, the average urinary IL-1β levels 
decrease to 1.01 pg/ml (Figure 3.4A) and was lower than the remaining OC patients.   
Thirteen patient samples of the age matched subset were further narrowed to 8 patients 
with a first degree family history of ovarian and/or breast cancer.  Average levels of urinary IL-
1β were higher in patients with a family history and benign ovarian disorder (0.99 pg/ml) or OC 
(6.33 pg/ml & 1.01 pg/ml) compared to patients with no family history of cancer and diagnosed 
as being healthy (0.93 pg/ml), having benign ovarian disorders (0.33 pg/ml), or having OC (1.16 
pg/ml) (Figure 3.4B). 
Urinary IL-1β levels correlate with body mass index (BMI). 
 Levels of urinary IL-1β were measured in 23 patient samples of the age matched subset 
and compared with patient BMI.    
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A. 
B.  
    
Figure 3.4. Urinary IL-1β levels correlate with familial history of cancer.  Urinary IL-1β was 
analyzed in triplicate by ELISA and data expressed as mean ± standard error in pg/ml in age 
match subset.  (A) Patients with family history of any cancer.  (B) Patients with family history of 
ovarian and/or breast cancer in first degree family members only.  
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The classifications of BMI as underweight, normal, overweight, and obese were according to 
World Health Organization standards (Table 3.2).  Patients classified with a normal BMI had the 
lowest average urinary IL-1β levels of 0.92 pg/ml (Figure 3.5A) while patients classified as 
overweight had average urinary IL-1β levels of 1.72 pg/ml or about double that found in normal 
BMI patients (Figure 3.5A).  Patients classified as obese had the highest average urinary IL-1β 
levels of 5.26 pg/ml; however, when samples 3119-2 and 3119-13 were excluding since IL-1β 
levels were at least 15-fold higher than similar samples, urinary IL-1β levels averaged 1.33pg/ml, 
still greater than patients with normal BMI (Figure 3.5A).  While a single patient classified as 
underweight had a urinary IL-1β level of 2.20 pg/ml (Figure 3.5A), overall urinary IL-1β levels 
appeared to increase with increasing BMI. 
 Further analyses of urinary IL-1β levels with BMI and clinical diagnosis revealed that 
healthy control patients had an average normal BMI of 22.12 and the lowest average urinary IL-
1β level of 0.67 pg/ml (Figure 3.5B).  Patients with benign ovarian disease fell within the obese 
BMI classification (31.94)) and demonstrated a 4-fold higher average urinary IL-1β level of 2.66 
pg/ml (Figure 3.5B) in comparison to the control group.  OC patients had an average BMI of 
29.13 classifying them as overweight and 4.7-fold higher average urinary IL-1β level of 3.15 
pg/ml (Figure 3.5B) in comparison to the control group.   
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A. 
B.  
 
Figure 3.5. Urinary IL-1β levels are elevated in patients with overweight and obese BMI 
classification.  (A) Urinary IL-1β levels in patient samples in relationship to BMI: Underweight 
(N=1), Normal (N=11), Overweight (N=2), Obese (N=9).  Urinary IL-1β was analyzed in 
triplicate by ELISA and data expressed as mean ± standard error in pg/ml in age match subset.  
(B) Average urinary IL-1β levels and average BMI per diagnosis category: Normal (N=2), 
Ovarian Benign (N=9), Ovarian Cancer (N=11).  Data expressed as mean ± standard error of 
BMI and mean urinary IL-1β in age match subset.  
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Discussion 
 While inflammation is an essential biological process for normal development and tissue 
homeostasis, it is also involved in a number of pathologic conditions including tissue injury, 
chronic inflammation, immunological diseases, and cancer [10].  Epidemiological studies have 
shown a link between chronic inflammation and risk for cancer as evidenced by prolonged 
infection with Heliocbacter pylori and gastric cancer, inflammatory bowel disease and colon 
cancer, and prostatitis and prostate cancer [11].  In the ovary, chronic inflammation resulting 
from repeated ovulatory wounding and repair promotes oxidative stress which enhances DNA 
replication errors and ultimately, oncogenesis [12].  Inflammation is regulated by several factors 
that can either promote or inhibit inflammation and since epithelial ovarian cancers (EOCs) are 
highly inflammatory, this pilot study evaluated urinary levels of the proinflammatory mediator, 
IL-1β against clinical parameters in order to gain a better understanding of this disease. Data 
from combined cohorts indicated elevated urinary IL-1β among OC patients compared to healthy 
controls or women with benign gynecologic disease.  Further, this study was able to evaluate 
four clinical parameters in relation to urinary IL-1β levels: (1) patient age, (2) diagnosis, (3) 
family history of cancer, and (4) BMI.   
 When I considered patient age at the time of sample collection, the highest levels of 
urinary IL-1β levels were found in the 20-29 and 30-39 years age groups followed by declining 
IL-1β levels as age increased.  In keeping with our findings and according to the American 
Society for Reproductive Medicine (ASRM), a woman’s potential reproductive capacity begins 
to gradually decline at approximately 32 years of age and more rapidly decreases after 37 years 
of age [13].  IL-1β has been suggested to play a role in female reproduction; specifically in 
ovulation and oocyte maturation, and inflammatory-linked mechanisms, such as production and 
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activation of proteolytic enzymes, prostaglandin production, nitric oxide production, cellular 
metabolism, and steroidogenesis [14, 15].  Therefore, it seems likely that after 40 years of age, 
there would be a decrease in urinary IL-1β levels as oocyte maturation and ovulation decrease in 
preparation for menopause. In contrast, however, Vural, et al. found higher plasma levels of IL-
1β in postmenopausal (≥48.6 years) women than in premenopausal (30.5 ± 2.5 years) women 
with levels of IL-1β decreasing below the premenopausal levels only after hormone replacement 
therapy [16]. Consequently, though the information was not readily available, perhaps the sharp 
decrease in urinary IL-1β levels seen in this study in women > 60 years may be due, in part, to 
the usage of hormone replacement therapy. 
 Urinary IL-1β levels alone had limited success in differentiating disease status.  Urinary 
IL-1β levels were higher in benign and cancer samples when compared to healthy controls, 
respectively.  IL-1β is present in the serum and ascites of OC patients [9] and has been shown to 
be involved with cancer tumorigenesis, angiogenesis, and metastasis [17].  The inability of 
urinary IL-1β to differentiate between benign and malignancy may be confounded by the 
inflammatory nature of so many benign and cancer conditions.  That is, many benign ovarian 
conditions develop in an inflammatory microenvironment.  For instance, endometrioma, a form 
of endometriosis in the ovary, is a highly inflammatory condition [18] which would expectedly 
result in high levels of urinary IL-1β [19].  However, proinflammatory markers including serum 
C-reactive protein (CRP), IL-6, and IL-8 have all been used in clinical studies to differentiate 
between normal, benign tumor, and OC [20-22].  Immunohistochemical analysis showed 
differential expression of IL-18 and its receptors in benign ovarian tumors, borderline ovarian 
tumors, and ovarian carcinomas [23].  Therefore, developing and employing a panel of 
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inflammatory mediators, including urinary IL-1β, may eventually benefit differential diagnostic 
and prognostic outcomes of OC. 
 Patient samples with confirmed family history of cancer were limited in this small pilot 
study.  Family history of cancer tended to relate to elevated urinary IL-1β in patients with 
ovarian benign disease and a first degree family history of ovarian and/or breast cancer. This 
supports the recent dualistic model that EOCs arise as either two types: Type 1 and Type 2 [24].  
Type 1 tumors may arise in a step-wise progression from a benign precursor lesion such as, the 
highly inflammatory condition, endometriosis.  Further, the prior tissue culture data using OSE 
cells with endogenous or exogenous BRCA1 185delAG revealed that this germline mutation 
increased expression and secretion of IL-1β, thereby potentially promoting a chronic 
inflammatory microenvironment (chapter 2). However, it is important to remember that not all 
individuals at risk for OC develop the disease so that secondary events, perhaps beyond a FH, 
may be necessary to promote disease. In keeping, I found minimal urinary IL-1β in healthy 
controls with a family history of any cancer which would most closely resemble the control cell 
model of FH IOSE 118 + PCDNA3.1 (chapter 3). 
Obesity as a risk factor of OC is controversial.  Recently, a meta-analysis of 47 
epidemiological studies found increased OC risk with high BMI [25].  The Ovarian Cancer 
Association Consortium investigated 15 case-control studies and found overweight and obese 
women were associated with increased risk of OC [26].  The National Institutes of Health also 
found that BMI was significantly associated with increased risk in women who never used 
hormone therapy [27].  Canchola, et al. found a positive association between OC risk and adult 
weight gain, waist circumference, and waist-to-hip ratio but no association to overall obesity as 
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classified by BMI [28].  In agreement, high waist-to-hip ratio was also associated with increased 
risk of OC but no association with BMI was found [29].     
Contradictory, some studies have found no relationship between obesity and risk of OC.  
Schouten, et al. reported no association overall between BMI and risk of OC; however, they did 
report a positive association among premenopausal women, but not in postmenopausal women 
[30].  More recent prospective studies reported no significant relationship between BMI and OC 
risk, irrespective of menopausal status [31, 32].  There was also no evidence for risk of OC and 
weight or weight gain among BRCA1 or BRCA2 mutation carriers [33].  Interestingly, Engleland 
et al. found the risk of OC was not associated with adult BMI, but suggested a possible increased 
risk in women who were obese in young adulthood [34]. 
In this study, one of the most apparent clinical features related to elevated urinary IL-1β 
was BMI.  I found increased urinary IL-1β levels associated with higher BMI.  Patients classified 
as overweight and obese were also likely to be diagnosed with OC and ovarian benign disorders, 
respectively, while concomitantly demonstrating the highest average urinary IL-1β levels.  In 
contrast, healthy controls with normal BMI exhibited the lowest average urinary IL-1β.  Among 
the data was a single patient case classified as underweight, but with elevated urinary IL-1β 
levels and a diagnosis of OC.  It is tempting to speculate that this individual may have had 
advanced OC at the time of sample collection where anorexia, nausea, and weight loss due to the 
increased glucose, lipid, and protein requirements of the tumor [35] could manifest as low BMI 
compounded with elevated urinary IL-1β as a result of advanced disease. 
The obesity and elevated IL-1β levels found in OC patients may contribute to OC 
mortality.  Studies have shown no association between pre-diagnosis (average 5 - 10 years prior 
to OC diagnosis) BMI and OC mortality [36, 37], but have also suggested obesity is associated 
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with poor outcome [38].  These contradictory findings may suggest that obesity itself is not the 
factor leading to increased OC mortality, but perhaps obesity acts as a comorbidity factor.  For 
instance, one factor that may contribute to poor outcome is the difficulty of proper chemotherapy 
dosages for obese patients.  A study of dosing practices of clinicians found a significant 
proportion of advanced OC patients were overweight or obese, as seen in the current study, and 
under-dosing of chemotherapy in obese populations was common even though this did not affect 
overall survival [39].  The variability in dosing when prescribing chemotherapy is largely due to 
concern for potential over-dosing and chemotherapy associated toxicities [40].  However, one 
may speculate dosing variability due to patient obesity may add to a patient’s poor outcome since 
the tumor is not getting the proper chemotherapy dose.  High mobility group A2 (HMGA2) is a 
protein that can regulate transcription by altering chromatin architecture and facilitate the 
assembly of multiprotein complexes of transcriptional factors [41] and is found expressed in 
serous OC tumors and not in normal ovarian epithelial cells [42].  OC tumors with high 
expression of HMGA2 and high BMI negatively affected overall survival; and high BMI 
negatively influenced the response to chemotherapy treatment [43]. 
Furthermore, obesity may increase tumor aggressiveness.  Increased metabolic activity 
and glucose concentrations are associated with highly aggressive OC cell lines [44].  The 
changes in metabolism and increase in glucose concentrations may occur as a result of the 
Warburg effect.  In cancer, the Warburg effect is regarded as a characteristic metabolic process 
that may contribute to cell survival in a stressful environment, such as the stress of chronic 
inflammation [45].  The Warburg effect suggests that cancer cells produce energy predominately 
by glycolysis and lactic acid production over oxidative phosphorylation [46].  An in vivo mouse 
model demonstrated increased tumor size with obesity and the tumors in the obese mice had a 
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unique molecular makeup with upregulated inflammation genes [47].  Obesity in OC patients 
may be further exacerbating the disease by contributing to an inflammatory environment.  
Obesity-related type 2 diabetes is associated with chronic inflammation [48-50] and IL-1β levels 
have been shown to be correlated with obesity and obesity related disorders.  Individuals with 
combined elevated plasma levels of IL-1β and IL-6 were at an increased risk for developing type 
2 diabetes [51].  Obese patients who underwent even mild weight loss had a 45% decrease in 
serum IL-1β levels over a three-year study period [52].  Leptin, an adipocytokine involved in the 
pathogenesis of insulin resistance necessary for developing type 2 diabetes, induces β-cell 
apoptosis and impaired β-cell function by promoting IL-1β production in human pancreatic islets 
[53].  Expression of leptin is also positively correlated with BMI [54].  In this study, obese 
patients may exhibit the highest urinary IL-1β levels as a result of obesity and the increased 
urinary IL-1β may be indicative of advanced disease.  
The greatest limitation of urinary IL-1β as a biomarker for OC is kidney function.  
Inflammatory mediators, including IL-1β, are typically found elevated in the urine and serum of 
patients with impaired kidney function [55-57].  Furthermore, elevated levels of IL-1β have been 
reported in vaginal secretions associated with gynecologic infections; however, Basso et al were 
unable to detect IL-1β in patient urine or serum [58].  Interestingly, two samples in our study, 
3119-2 and 3119-13, displayed unusually elevated urinary IL-1β in comparison to their 
counterparts.  Such marked urinary IL-1β levels may be attributed to possible kidney injury or 
gynecological infection.   
The data in this chapter has been derived from a small pilot study.  However, the sample 
size of this study is in keeping with other published pilot studies examining IL-1β in urine, 
serum, and plasma [16, 55, 57-60].  My study had limited statistical significance which may be 
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associated to the small sample size.  Furthermore, a normal baseline value for urinary IL-1β in 
women has not yet been established in the literature [61].  Therefore, future study and increased 
sample size may assist in the development of baseline and threshold values that could be used to 
differentiate between healthy, benign disorders, OC, as well as other clinical parameters such as 
metabolic disruption.  Lastly, this study also supports the theory of elevated urinary IL-1β being 
associated with cancer progression such that the identification of an inflammatory profile 
specific to EOC may benefit non-invasive diagnostic and prognostic applications as well as lead 
to the development of adjuvant therapies utilizing target-specific anti-inflammatory treatments to 
reduce the mortality associated with this disease.    
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Chapter 4: 
 
Molecular Characterization and Comparison of wtBRCA1 and Founder Mutations, 
BRCA1 185delAG and BRCA1 5382inC 
 
Introduction 
 The breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor that when 
mutated is associated with increased breast and ovarian cancer (OC) risk [1, 2].  The best 
characterized BRCA1 germline mutations are the founder mutations, BRCA1 185delAG and 
5382insC [3, 4]; and these mutations are associated with the majority of OC cases in the 
Ashkenazi Jewish community. 
 While these mutations are not susceptible to nonsense-mediated messenger RNA 
(mRNA) decay suggesting that viable mutant proteins could be produced [5, 6], these protein 
products have not been isolated in vivo or in vitro.  The difficulty of locating these mutant 
protein products by antibody is made especially difficult due to their homology with wild-type 
BRCA1 (wtBRCA1).  Therefore, to date, all studies of the BRCA1 185delAG employed PCR 
confirmation of the mutation and all functional changes seen in mutation carrying cell lines are 
believed to be the result of a novel truncated protein (yet to be visualized by protein study).  
Even so, my lab has described several functions of the BRCA1 185delAG mutation, including 
enhanced apoptosis in response to chemotherapy treatment [7, 8], increased expression of 
adhesion and metastasis proteins (Linger in process), and increased expression of 
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proinflammatory mediators (chapter 2).  In order to better understand the function of the 
predicted BRCA1 185delAG truncated protein, BRAT, I produced the BRCA1 185delAG 
mutated protein that can be utilized in future functional studies.  I also describe potential 
characteristics of the putative BRCA1 185delAG and 5382insC mutation proteins based on 
amino acid sequence characteristics. 
 
Materials and Methods 
Plasmid Construction and Transfection 
 cDNA encoding for BRCA1 185delAG with an N-terminal His-tag and C-terminal S-
protein motif was generated by Midland Certified Reagent Company (Midland, TX) using the 
published genbank BRCA1 sequence U14680.  S-His-BRAT cDNA was then ligated using T4 
DNA ligase (New England Biolabs) in 1X T4 ligase buffer (50mM Tris-HCl (pH7.5), 10 MgCl2, 
10mM dithiothreitol, 2mM ATP, 25ug/ml BSA) into the pTriEx-4 plasmid (Novagen), 
transformed into DH5α competent cells and isolated under standard conditions (Invitrogen).  The 
S-His-BRAT plasmid sequence was confirmed. 
Protein Expression and Immunoprecipitation 
DH5α competent cells transformed with S-His-BRAT cDNA were grown in 3 ml LB 
broth with ampicillin (100mg/L) overnight at 37°C, shaking at 250 rpm.  The next day, the 
microbial culture was transferred into 1L of LB broth with ampicillin (100mg/ml) shaking at 250 
rpm, at 37°C.  When A600 reached 0.7-1, 0.2 g/ml stock IPTG was added at a concentration of 
0.2g/L to induce protein expression.  The culture was grown overnight at 37°C shaking at 250 
rpm.  Cells were harvested and washed in PBS by centrifugation at 4°C for 15 minutes at 
2500×g.  Cell pellet was incubated with 3 ml ice cold RIPA buffer at 4°C for 10 minutes and 
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cells were disrupted by repeated aspiration through a 21 gauge needle.  Cell lysate was incubated 
with 2 ug of primary antibody for 1 hour at 4°C.  Protein A/G agarose suspension was added to 
lysate and antibody mixture followed by incubation at 4°C on a rocker overnight.  The 
suspension was collected by centrifugation at 500 x g for 2 minutes at 4°C.  The cell pellet was 
washed with RIPA buffer containing protease inhibitors followed by analysis for IP confirmation 
of 185delAG production and isolation by western blot as described in chapter 2. 
Simultaneous SDS-PAGE analysis was conducted.  The SDS-PAGE was stained with 
coomassie blue and the visualized 185delAG protein band was excised and amino acid 
sequenced at the H. Lee Moffitt Cancer Center and Research Institute.  Antibodies: His tag 
(27E8) (1:1000) Cat. #2366S Cell Signaling Technology (Beverly, MA) and BRCA1 (Ab-1) 
(1:1000) Cat. # OP92 Calbiochem (Billerica, MA).   
Peptide Mapping 
 Following in-gel tryptic digestion, peptides were extracted and concentrated under 
vacuum centrifugation.  A nanoflow liquid chromatograph (Easy-nLC, Proxeon, Odense, 
Denmark) coupled to an electrospray ion trap mass spectrometer (LTQ, Thermo, San Jose, CA) 
was used for tandem mass spectrometry peptide sequencing experiments.  The sample was first 
loaded onto a trap column (BioSphere C18 reversed-phase resin, 5µm, 120Å, 100 µm ID, 
NanoSeparations, Nieuwkoop, Netherlands) and washed for 3 minutes at 8 µL / minute.  The 
trapped peptides were eluted onto the analytical column, (BioSphere C18 reversed-phase resin, 
150mm, 5µm, 120Å, 100 µm ID, NanoSeparations, Nieuwkoop, Netherlands).  Peptides were 
eluted in a 60 minute gradient from 5% B to 45% B (solvent A: 2% acetonitrile + 0.1% formic 
acid; solvent B: 90% acetonitrile + 0.1% formic acid) with a flow rate of 300 nl/min.  Five 
tandem mass spectra were collected in a data-dependent manner following each survey scan.  
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Sequences were assigned using Mascot (www.matrixscience.com) searches against human 
International Protein Index entries.  Carbamidomethylation of cysteine, methionine oxidation, 
and deamidation of asparagine and glutamine were selected as variable modifications, and as 
many as 2 missed tryptic cleavages were allowed.  Precursor mass tolerance is set to 2.5 and 
fragment ion tolerance to 0.8.  Results from Mascot were compiled in Scaffold, which was used 
for manual inspection of peptide assignments and protein identifications. 
Computational Characterization of Disorder 
 The distribution of intrinsic disorder propensity in BRCA1, 185delAG, and 5382inC was 
analyzed using three algorithms, PONDR® VLXT [9], PONDR® VSL2 [10], and PONDR-FIT 
[11].  PONDR® VLXT is capable of identifying potential molecular interactions motifs in 
disordered proteins and disordered protein regions [12, 13].  PONDR® VSL2 more accurately 
predicts general protein disorder [10], whereas PONDR-FIT is a meta-predictor that combines 
six individual predictors [11], such as PONDR® VLXT [9], PONDR® VSL2 [10], PONDR® VL3 
[14], FoldIndex [15], IUPred [16], and TopIDP [17].  This meta-predictor is moderately more 
accurate than each of the component predictors and provides accurate disorder predictions at the 
residue level, which allows evaluation of the number and size of the predicted disordered protein 
segments. 
Evaluation of the Aggregation Propensity 
 Prediction of aggregation-prone regions within the protein of interest was achieved 
utilizing the consensus web tool, AmylPred2 (http:// http://aias.biol.uoa.gr/AMYLPRED2/) [18]; 
which includes the following methods: Aggrescan [19], AmyloidMutants [20], Amyloidogenic 
Pattern [21], Average Packing Density [22], Beta-strand contiguity [23], Hexapeptide 
Conformational Energy [24], NetCSSP [25], Pafig [26], SecStr (Possible Conformational 
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Switches) [27], Tango [28], and Waltz [29].  AmylPred2 recognizes amyloid structures; a 
specific subset of insoluble fibrous protein aggregates [18].  Web tool PASTA2.0 
(http://protein.bio.unipd.it/pasta2/) was also utilized to predict aggregation-prone regions; as well 
as, intrinsic disorder and secondary structure [30]. 
Prediction of Post-Translational Modifications 
 Ubiquitination sites were predicted using the UbPred predictor [31].  UbPred is a random 
forest predictor with an accuracy of 72%.  Sumoylation sites were predicted using SUMOplot™ 
Analysis Program (Abgent Tools) (http:// http://www.abgent.com/sumoplot).  Phosphorylation 
and glycosylation sites were predicted using HMMpTM (http:// 
http://aias.biol.uoa.gr/HMMpTM/index.php) [32]. 
ANCHOR Analysis 
 Potential protein binding sites were identified by the ANCHOR algorithm [33, 34].  This 
algorithm is based on the hypothesis that long regions of disorder contain localized potential 
binding sites that cannot form enough favorable intra-chain interactions to fold on their own, but 
are likely to gain stabilizing energy by interacting with a globular protein partner.  The PredZinc 
version 1.4 server was utilized to predict possible zinc binding domains in the amino acid 
sequence [35]. 
Signal Peptide Analysis 
 The SignalP 4.1 server was utilized to predict the presence and location of secretory 
pathway signal peptide cleavage sites in the amino acid sequence of the target protein [36].  This 
method incorporates a prediction of cleavage sites and a signal peptide/non-signal peptide 
prediction based on a combination of several artificial neural networks.   
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Secondary Structure 
 Prediction of the secondary structure for the target protein was determined by GOR IV 
(http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_gor4.html) [37] and PORTER 
(http://distill.ucd.ie/porter/) [38].  These programs analyze multiple sequence alignments and the 
highest probability of each secondary structure at each amino acid position.  GOR IV produces 
the highest probability compatible with a predicted helix segment of at least four residues and a 
predicted extended segment of at least two residues. 
Domain Homologue Analysis 
 SBASE (http://www.icgeb.trieste.it/sbase) is a web tool that encompasses protein domain 
sequences to facilitate the detection of domain homologues [39].  This tool utilizes sequence 
alignment to find similar amino acid domains that are of biological significance to the structure 
and/or function of a target protein.  National Center for Biotechnology Information (NCBI) Basic 
Local Alignment Search Tool (BLAST) was utilized to align amino acid sequences in order to 
find sequence similarities (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
 
Results 
BRCA1 185delAG protein produced in competent E. coli cells was isolated by 
immunoprecipitation. 
 There was no His-tagged protein in the expected 5kDa range for the 185delAG protein.  
However, a His-tagged protein in the 10kDa to 20kDa range was produced and isolated from 
competent E. coli cells by immunoprecipitation as seen by western blot (Figure 4.1A).  The 
resulting protein amino acid sequence from an offsite protein sequencing core at H. Lee Moffitt 
Cancer Center Proteomics Core confirms BRCA1 185delAG (Figure 4.1B).  The expected 
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protein size of the 38 amino acid BRCA1 185delAG is about 5kDa and was compared to the 
208kDa wtBRCA1 and 204kDa BRCA1 5382insC (Table 4.1). 
BRCA1 185delAG is a structurally ordered protein. 
Multiple prediction software programs were utilized to identify molecular characteristics 
of wild-type BRCA1 (wtBRCA1), BRCA1 185delAG, and BRCA1 5382insC as summarized in 
Table 4.1.  The amino acid sequence of each protein target was utilized to predict the stability of 
their respective tertiary structure.  wtBRCA1 had regions of order and disorder throughout the 
protein sequence (Figure 4.2A).  The PONDR Score was below the standard threshold and 
confirmed wtBRCA1 as a disordered protein (Figure 4.2B).  Protein mean hydropathy, an 
average of the values that are assigned to amino acids of a target protein representing the 
hydrophobic or hydrophilic properties of its’ side-chain [40], was also investigated.  wtBRCA1 
was predicted to have a low mean hydropathy and a low overall protein charge suggesting 
wtBRCA1 is a hydrophilic protein and was further confirmed to be disordered (Figure 4.2C). 
By contrast, BRCA1 185delAG was predicted to be a highly ordered protein with two 
small regions of disorder in the N and C-terminals (Figure 4.3A & B).  The PONDR Score fell 
above the standard threshold and confirmed 185delAG as an ordered protein (Figure 4.3C).  The 
high mean hydropathy and a low overall net protein charge suggested that it is a hydrophobic 
protein and further confirmed BRCA1 185delAG as an ordered protein (Figure 4.3D).  BRCA1 
5382insC had regions of order and disorder as seen in wtBRCA1 (Figure 4.4A).  The PONDR 
Score was below the standard threshold and confirmed 5382insC as a disordered protein (Figure 
4.4B).   
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A. 
 
 
 
 
 
 
 
B. 
 
 
Figure 4.1. BRCA1 185delAG protein expression and peptide mapping.  (A) Western blot 
visualization of BRCA1 185delAG protein isolated by immunoprecipitation with His tag 
antibody.  (Left) BRCA1 antibody western blot with ladder in lane 1 and immunoprecipitation in 
lanes 2 and 3.  (Right) His tag antibody western blot with ladder in lane 1 and 
immunoprecipitation in lanes 2 and 3.  Black arrow shows band excised for amino acid 
sequencing.  Blue arrow shows expected size of 185delAG ~5kDa.  (B)  Peptide mapping results 
from H. Lee Moffitt Cancer Center Proteomics Core. 
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30 kDa 
 
 
 
9 kDa 
 
13 of 22 (59%) amino acid match 
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Table 4.1 Molecular Characterization Comparison 
    
 wtBRCA1 185delAG 5382insC 
# Amino Acids 1863 39 1828 
Predicted size 208kDa 5kDa 204kDa 
Disordered or 
Ordered 
Disordered Ordered Disordered 
Potential Protein 
Binding Sites 
44 0 44 
Phosphorylation 
Sites 
251 5 245 
Glycosylation 
Sites 
4 0 7 
Sumoylation 
Sites 
33 0 34 
Ubiquitination 
Sites 
67 1 66  
Signal Peptides No No 0 
Amyloid 
Formation Sites 
(% of amino 
acid sequence) 
20 (1%) 12 (31%) 20 (1%) 
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A.       B. 
       
C. 
 
 
Figure 4.2. Predicted intrinsic disorder and hydrophobicity of wtBRCA1.  PONDR analysis 
of wtBRCA1 showed locations of intrinsically ordered and disordered regions in protein 
sequence (A) and overall protein classification (B & C). 
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A.       B. 
              
 
         
C.       D. 
                          
Figure 4.3. Predicted intrinsic disorder and hydrophobicity of BRCA1 185delAG.  PONDR 
analysis of BRCA1 185delAG showed locations of intrinsically ordered and disordered regions 
in protein sequence (A & B) and overall protein classification (C & D). 
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A.       B. 
    
C. 
 
Figure 4.4. Predicted intrinsic disorder and hydrophobicity of BRCA1 5382insC.  PONDR 
analysis of 5382insC showed locations of intrinsically ordered and disordered regions in protein 
sequence (A) and overall protein classification (B & C). 
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BRCA1 5382insC was predicted to have a low mean hydropathy and a low overall protein 
charge suggesting BRCA1 5382insC is a hydrophilic protein and was further confirmed to be 
disordered (Figure 4.4C). 
BRCA1 185delAG has no potential protein or zinc binding sites. 
 The potential protein binding sites for wtBRCA1, BRCA1 185delAG, and BRCA1 
5382insC were identified by prediction software, ANCHOR.  wtBRCA1 had several potential 
protein binding regions throughout the length of the protein sequence (Figure 4.5A).  BRCA1 
5382insC also had several potential protein binding regions in a pattern similar to wtBRCA1 
(Figure 4.5B).  BRCA1 185delAG had no potential protein binding regions and also had no 
predicted zinc binding domains (Figure 4.5C, D), while wtBRCA1 and 5382insC showed 
potential zinc binding domains (Figure 4.5E, F). 
BRCA1 185delAG has limited potential post-translational modification sites. 
 I analyzed for the presence of potential post-translational modification sites, 
phosphorylation, glycosylation, ubiquitination, sumoylation, and secretory pathway signal 
peptides, in each protein target (Table 4.1).  All three protein targets contained potential 
phosphorylation and ubiquitination sites.  However, while wtBRCA1 and BRCA1 5382insC had 
potential glycosylation and sumoylation sites, BRCA1 185delAG had no potential glycosylation 
or sumoylation sites.  Each protein target, wtBRCA1 (Figure 4.6A), BRCA1 5382insC (Figure 
4.6B), and BRCA1 185delAG (Figure 4.6C), had no potential signal peptides.   
BRCA1 185delAG is potentially highly self-aggregated. 
 Protein self-aggregation software was used to predict the aggregation tendencies of each 
protein target.  Both wtBRCA1 (Figure 4.7A) and BRCA1 5382insC (Figure 4.7B) had a few 
potential sites of amyloid formation/self-aggregation.   
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A. 
 
 
 
B. 
 
C. 
 
Figure 4.5. Potential protein binding and zinc binding domains.   
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D. 
 
E. 
 
F. 
 
Figure 4.5. Continued. Potential protein binding and zinc binding domains.  ANCHOR 
analysis showed the locations of potential protein binding domains of wtBRCA1 (A), BRCA1 
5382insC (B), and BRCA1 185delAG (C).  (D). PredZinc analysis showed the lack potential zinc 
binding domains in BRCA1 185delAG.  (E). PredZinc analysis showed presence of zinc binding 
domains in wtBRCA1.  (F). PredZinc analysis showed presence of potential zinc binding 
domains in BRCA1 5382insC.  
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A. 
 
B.  
 
Figure 4.6. Potential signal peptides.   
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C. 
 
 
Figure 4.6 Continued. Potential signal peptides.  SignalP 4.1 server predicted the presence of 
signal peptides in wtBRCA1 (A), BRCA1 5382insC (B), and BRCA1 185delAG (C). 
 
A. 
 
B. 
 
C. 
 
Figure 4.7. Prediction of amyloid formation.  PASTA2.0 predicted the number of potential 
amyloid formation sites in wtBRCA1 (A), BRCA1 5382insC (B), and BRCA1 185delAG (C).   
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These proteins had only 20 sites of potential amyloid formation, about 1% of the entire amino 
acid sequence.  These sparing potential sites of self-aggregation led to the classification of “No” 
in Table 4.1 under the “Self-Aggregate” category.  BRCA1 185delAG (Figure 4.7C) had 12 
potential amyloid formation sites, about 31% of the entire amino acid sequence.  Analysis of 
which 185delAG residues would potentially bind during self-aggregation showed the central, 
highly ordered region would be the likely location of aggregation, while the more disordered 
regions in the N and C-terminals showed no potential of aggregation (Figure 4.8A-C).   
BRCA1 185delAG secondary structure is mostly alpha helical. 
 The secondary structure composition of each protein target was analyzed.  Each target 
was comprised of alpha helix, extended strands, and random coil.  The wtBRCA1 (Figure 4.9A) 
and BRCA1 5382insC (Figure 4.9B) had similar secondary structure composition.  The 
wtBRCA1 and BRCA1 5382insC both had 32% alpha helix structures; wtBRCA1 had 13% 
extended strand and BRCA1 5382insC had 12% extended strand; and, wtBRCA1 had 55% 
random coil and BRCA1 5382insC had 56% random coil.  BRCA1 185delAG (Figure 4.9C) was 
mostly composed of alpha helix (45%), followed by 42% random coil, and 13% extended strand. 
In BRCA1 185delAG, the area with the greatest potential for aggregation is also 
composed of the alpha helix conformation, while the random coil and extended strands are 
located in areas of disorder with less potential for aggregation (Figure 4.10 A, B, C).  The 
potential protein schematic showed that the BRCA1 185delAG protein is organized with random 
coil at the N-terminus that leads to an alpha helix structure followed by a second small region of 
random coil and ending with extended strand and random coil (Figure 4.10D).   
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A.      B. 
 
C. 
 
Figure 4.8. Prediction of combined amyloid formation and aggregation.  (A). PASTA 2.0 
predicted self-aggregation at each amino acid residue of 185delAG.  (B). Illustrative schematic 
of 185delAG self-aggregation with the location of amino acids aggregating at blue dots.  (C). 
Graph predicting aggregation in terms of ordered regions and disordered regions of 185delAG. 
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A. 
 
Sequence length :  1863 
GOR4 : 
   Alpha helix     (Hh) :   592 is  31.78% 
   310  helix       (Gg) :     0 is   0.00% 
   Pi helix        (Ii) :     0 is   0.00% 
   Beta bridge     (Bb) :     0 is   0.00% 
   Extended strand (Ee) :   241 is  12.94% 
   Beta turn       (Tt) :     0 is   0.00% 
   Bend region     (Ss) :     0 is   0.00% 
   Random coil     (Cc) :  1030 is  55.29% 
   Ambigous states (?)  :     0 is   0.00% 
   Other states         :     0 is   0.00% 
 
B. 
Sequence length :  1828 
GOR4 : 
   Alpha helix     (Hh) :   589 is  32.22% 
   310  helix       (Gg) :     0 is   0.00% 
   Pi helix        (Ii) :     0 is   0.00% 
   Beta bridge     (Bb) :     0 is   0.00% 
   Extended strand (Ee) :   224 is  12.25% 
   Beta turn       (Tt) :     0 is   0.00% 
   Bend region     (Ss) :     0 is   0.00% 
   Random coil     (Cc) :  1015 is  55.53% 
   Ambigous states (?)  :     0 is   0.00% 
   Other states         :     0 is   0.00% 
 
C. 
        10        20        30 
         |         |         | 
MDLSALRVEEVQNVINAMQKILVSHLSGVDQGTCLHKV 
ccccccchhhhhhhhhhhhhhhhhccccccceeceeec 
Sequence length :    38 
GOR4 : 
   Alpha helix     (Hh) :    17 is  44.74% 
   310  helix       (Gg) :     0 is   0.00% 
   Pi helix        (Ii) :     0 is   0.00% 
   Beta bridge     (Bb) :     0 is   0.00% 
   Extended strand (Ee) :     5 is  13.16% 
   Beta turn       (Tt) :     0 is   0.00% 
   Bend region     (Ss) :     0 is   0.00% 
   Random coil     (Cc) :    16 is  42.11% 
   Ambigous states (?)  :     0 is   0.00% 
   Other states         :     0 is   0.00% 
Figure 4.9. Secondary structure composition.  GOR4 server predicts the secondary structure 
composition of wtBRCA1 (A), BRCA1 5382insC (B), and BRCA1 185delAG (C).  
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A.             B. 
 
C.              D. 
 
 
Figure 4.10. Distribution of secondary structure throughout BRCA1 185delAG protein.  
PASTA2.0 analysis of BRCA1 185delAG graphs the location of alpha helix (A), extended strand 
(B), and random coil (C) along with predicted location of aggregation.  (C). Illustrative diagram 
of secondary configuration. 
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BRCA1 185delAG resembles Peptidase M20. 
 In order to understand the function of BRCA1 185delAG in the cell, I analyzed the amino 
acid sequence using SBASE prediction software to identify other similar proteins.  Analysis of 
domain similarities in the BRCA1 185delAG and other proteins showed a predicted Peptidase 
M20-like domain (Figure 4.11).  Alignment of the BRCA1 185delAG amino acid sequence to 
the Peptidase M20 amino acid sequence showed the N and C-terminals of BRCA1 185delAG 
were the domains of similarity (Figure 4.12).    
 
Discussion 
 While founder mutations, BRCA1 185delAG and BRCA1 5382insC, are associated with 
increased risk of OC, the molecular characterization of their potential protein products has not 
been reported.  Therefore, I sought to begin early characterization of these proteins to better 
understand their role in OC oncogenesis.  Our previous studies have focused on the BRCA1 
185delAG mutation; however, I wanted to compare this mutation to the BRCA1 5382insC 
mutation to investigate what characteristics may be shared by founder mutations and which are 
distinct to the BRCA1 185delAG.  Overall, the study results showed the BRCA1 185delAG  
protein product is structurally and molecularly distinct from the wtBRCA1 while BRCA1 
5382insC more closely resembles wtBRCA1. 
Predictably, the BRCA1 185delAG mutation lost many of the post-translational 
modification sites since it has lost the majority of the wtBRCA1 protein.  In contrast, BRCA1 
5382insC has retained many of the potential post-translational modification sites since it has 
retained much of the wtBRCA1 protein.  Furthermore, both BRCA1 185delAG and BRCA1 
5382insC had no potential secretory signal peptides similar to wtBRCA1.    
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Raw output (SwissProt format) 
ID   SBASE_PRED     STANDARD;      PRT;   38 AA 
AC   unknown; 
DE   DOMAIN ARCHITECTURE PREDICTED BY SBASE SVM 
KW 
FT   DOMAIN      1    35       Peptidase M20 - like domain; 
SQ   SEQUENCE   38 AA; 
     MDLSALRVEE VQNvINAMQK ILVSHLSGVD QGTCLHKV  
Figure 4.11. BRCA1 185delAG contains a Peptidase M20-like domain.  SBASE server 
analysis of BRCA1 185delAG. 
 
 
Alignment statistics for match #1 
Score Expect Method Identities Positives Gaps Frame 
12.7 bits(21) 1.7()  4/4(100%) 4/4(100%) 0/4(0%)  
Features: 
Query  35   LHKV  38 
            LHKV 
Sbjct  219  LHKV  222 
 
Alignment statistics for match #2 
Score Expect Method Identities Positives Gaps Frame 
12.4 bits(20) 2.3()  4/7(57%) 5/7(71%) 0/7(0%)  
Features: 
Query  6   LRVEEVQ  12 
           LR+  VQ 
Sbjct  20  LRIRTVQ  26 
Figure 4.12. Peptidase M20 and BRCA1 185delAG sequence alignment.  BLAST shows 
regions and corresponding amino acid sequence of BRCA1 185delAG with commonality to 
Peptidase M20.  
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Since neither mutation gained the attributes needed to independently enter the secretory pathway, 
it is likely that both mediate oncogenic changes within the cell and not by extracellular receptor 
binding.  wtBRCA1 is located in and functions mainly in the nucleus, so one might speculate that 
BRCA1 185delAG and BRCA1 5382insC also function within the nucleus.  The presence of 
BRCA1 185delAG and BRCA1 5382insC in the nucleus may allow them to independently 
influence nuclear processes such as, DNA replication, cell cycle signaling, and transcription 
factor recruitment as seen in wtBRCA1 [2].  wtBRCA1 has two nuclear localization signals 
(NLSs) [41, 42] and a nuclear export signal (NES) [43] that allows it to shuttle between nuclear 
and cytoplasmic compartments [44, 45].  Potentially, the BRCA1 5382insC may also shuttle in 
and out of the nucleus since the NLS and NES domains are still intact.  However, the NLS and 
NES domains are lost in the BRCA1 185delAG, so it is unlikely that this mutation can 
independently transport out of the nucleus and is in keeping with our earlier report that BRCA1 
185delAG is located within the nucleus [7].        
Ordered proteins adopt energetically stable three-dimensional conformations with 
minimum free energy based upon the sequence of the amino acids in their polypeptide chain.  
More recently, a new category of proteins has been discovered known as intrinsically disordered 
proteins (IDPs) which cannot adopt an energetically favorable three-dimensional conformation, 
due to their unique amino acid sequence arrangement; and, therefore, lack a stable tertiary 
structure in vitro [46].  Their dynamic tertiary structure allows IDPs to be involved in multiple 
functional pathways, conferring multiple regulatory functions [47-49].  Mutations in and 
dysregulation of IDPs has been associated with many diseases, including cancer [49-51].  The 
tumor suppressor p53 is an IDP and functions via its C-terminal intrinsically disordered region 
(IDR) that simultaneously exists in differing three-dimensional conformations that each have 
111 
 
unique functions [50].  Phosphatase and tensin homologue (PTEN) is a frequently mutated tumor 
suppressor that governs many cellular processes including survival, proliferation, energy 
metabolism, and cellular architecture [52].  PTEN deficiency or dysregulation drives 
endometrial, prostate, brain and lung cancers and causes neurological defects [53, 54].  PTEN 
has been identified as an IDP with an IDR in the C-tail which is known to regulate the majority 
of PTEN functions and protein interactions [55].   
BRCA1 has been shown to be an IDP with the majority of the central region as its IDR, 
which is able to mediate interactions with DNA and p53 [56].  BRCA1 is also a hydrophilic 
protein which would allow for enhanced interactions with other proteins as evident by the many 
potential protein binding sites seen in this study [57-63].  Conversely, the BRCA1 185delAG 
mutation is a very ordered, hydrophobic protein that showed no potential protein binding sites.  
BRCA1 185delAG is as an example of an IDP (BRCA1) mutated to an ordered protein 
(185delAG) and subsequently being associated with increased cancer risk.  Further, study is 
clearly warranted to determine if transition of BRCA1 via mutation from disorder to order could 
be utilized as predictor of the likelihood of oncogenic transformation in specific mutations.  
 Interestingly, the highly hydrophobic BRCA1 185delAG with no potential protein 
binding partners seems to have a high potential to self-aggregate.  This may explain the previous 
difficulty our lab has encountered in attempting to isolate this protein in vitro from ovarian 
surface epithelial cells.  Also, the isolated His tagged protein in this study was larger than the 
expected size of the protein and self-aggregation would explain this phenomenon.  Perhaps self-
aggregation is necessary for its’ deleterious properties as seen in other diseases.  Protein 
aggregation can result in a variety of neurodegenerative and non-neuropathic disorders such as 
Huntington’s disease, Parkinson’s disease, thrombosis and type 2 diabetes [64].  Aggregation of 
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gain of function mutant p53 has also been shown to contribute to the development of cancer [65].  
α1-Antitrypsin deficiency (AATD) is a genetic disorder that can lead to chronic obstructive 
pulmonary disease (COPD) in adults and/or liver disease in infants, children, and adults [66].  It 
is characterized by the pathogenic polymerization of α1-antitrypsin protein that induces cellular 
damage by large aggregates [66].  The potential self-aggregation of BRCA1 185delAG may 
induce cellular damage resulting in the development of chronic inflammation as seen in chapter 2 
by the increased endogenous production of IL-1β and the possibility of oncogenic 
transformation. 
 Unanticipated, I found that BRCA1 185delAG contains an alpha helical secondary 
structure which is an uncommon trait of self-aggregating proteins.  Self-aggregating proteins are 
mainly composed of beta sheets [67]; although, some studies have suggested an intermediate step 
in amyloid formation that consists of an alpha helix to beta sheet folding transition [68, 69].  
BRCA1 185delAG is a very small protein of only 38 amino acids making it unlikely to fold into 
a β-sheet structure during aggregation. 
In an attempt to begin to understand the functions of BRCA1 185delAG in the cell, I 
looked to proteins with similar amino acid sequences and found a resemblance to the Peptidase 
M20 family.  This is a group of proteins that contains metallopeptidases and non-peptidase 
homologues or amidohydrolases that belong to the MEROPS peptidase family M20 [70].  These 
peptidases have two catalytic zinc ions at the active site.  While wtBRCA1 has a RING finger 
domain that utilizes the binding of two zinc ions [2], the BRCA1 185delAG mutation has lost 
this domain [71] and zinc binding analysis of BRCA1 185delAG showed that no potential zinc 
binding properties were retained.  Consequently, it is unlikely that BRCA1 185delAG functions 
in a metallopeptidase-like manner.  However, a secondary function of the Peptidase M20 family 
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of proteins is amidohydrolase.  The amidohydrolase superfamily is a group of enzymes that 
undergo catalytic reactions involving amino acids, sugars, nucleic acids, and organophosphate 
esters [72].  The amidohydrolase active site contains a metal ion including zinc, iron, copper, and 
calcium [72].  Histone deacetylase (HDAC) is an example of a zinc-dependent amidohydrolase 
which functions to catalyze the removal of an acetyl group from DNA in the nucleus by cleaving 
a non-peptide amide bond resulting in a more positively charged DNA molecule which then 
more tightly coils around histones making DNA less available for transcription [73].  It is 
tempting to speculate that the BRCA1 185delAG could possibly act in a similar fashion to inhibit 
transcription of target genes that have tumor suppressor qualities which may be facilitated by the 
binding of a non-zinc metal ion to the IDRs of the N or C-terminals. 
 This study is the first examination of the biochemical, molecular and structural 
composition of the putative BRCA1 185delAG truncation protein.  The BRCA1 185delAG 
protein is structurally and molecularly distinct from wtBRCA1 and fellow founder mutation, 
BRCA1 5382insC.  To date, the protein product of BRCA1 185delAG has not been isolated.  I 
was able to produce, isolate, and confirm the sequence of the protein.  Allowing for further 
protein analysis, such as confirmation of its 3D protein structure, self-aggregation, helical 
folding and possible protein-DNA interactions leading to a better understanding of its’ 
oncogeneic functions.  
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Chapter 5:  
 
Concluding Remarks 
 
 This study examined the molecular influence of the BRCA1 founder mutation, 
185delAG, in normal OSE.  I found that the BRCA1 185delAG mutation confers a potentially 
unique premalignant condition that implicates a role for inflammation in ovarian transformation 
by altering the expression of the proinflammatory mediator, IL-1β.  Enhanced expression of IL-
1β could result in a state of chronic inflammation that when coupled with rapid ovulatory-
dependent OSE cell division directly or indirectly through downstream targets, IL-6 and IL-8, 
promotes genetic instability leading to malignant transformation.  In agreement, this study 
showed enhanced levels of urinary and serum IL-1β in OC patients supporting an inflammatory 
OC environment.  In addition to suggesting how the BRCA1 185delAG may increase risk for 
OC, my data also have implications for OC metastasis, emergence of drug-resistant disease, and 
unique treatment options, respectively. 
Inflammation present in OC may promote metastasis.  An in vivo mouse model of 
spontaneous metastasis demonstrated that tumor cell dissemination from the ovaries correlated 
temporally with enhanced peritoneal inflammation and depletion of peritoneal macrophages 
reduced metastasis suggesting a macrophage-mediated mechanism of inflammation [1].  
Macrophage-secreted TNF-α, a proinflammatory mediator, is also able to increase tumor cell 
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invasiveness [2] while adipocyte-secreted proinflammatory cytokines, IL-6 and IL-8, attracted 
OC cells to the omentum.   
Further, OC metastasis is defined by an epithelial-mesenchymal transformation (EMT).  
EMT is characterized by the disruption of cellular junctions and loss of cellular polarity resulting 
in morphologic modulation into a fibroblastic phenotype accompanied by increased cell motility 
and invasion [3]. Embryonically, EMT contributes to gastrulation, and in the ovary to gonadal 
development [4].  EMT and subsequent mesenchymal-epithelial (MET) transitions associated 
with alterations of E-cadherin expression [5] are among the most dramatic examples of OSE 
plasticity in response to its microenvironment and represent critical steps in ovarian tumor 
progression.  Owing to the mesodermal origin of OSE, normal OSE express N-cadherin, but not 
E-cadherin.  However, in contrast to loss of E-cadherin expression with tumor progression in 
most epithelial cancers, E-cadherin is often re-expressed in OSE lining crypts and inclusion cysts 
as well as in benign, borderline and primary OCs [5].  Importantly, given that OC metastasizes 
by shedding into the peritoneal cavity as single cells or cell clusters, transient E-cadherin re-
expression maintains OC aggregate formation and survival in the peritoneal cavity [6].  OC 
aggregates, mesothelial cells and surrounding blood cells all secrete cytokines that support OC 
survival in ascites so that both autocrine and paracrine mechanisms sustain OC EMT in ascites 
fluid and promote establishment of metastatic disease.  The reverse process of MET results from 
loss of transient E-cadherin expression so that established metastatic OCs are frequently devoid 
of E-cadherin [7].  Pathways promoting EMT in OSE rely on complex interactions between OSE 
and its extracellular components and consist of autocrine and paracrine interactions with 
hormones and cytokines including transforming growth factor-β [8], epidermal growth factor [9], 
hepatocyte growth factor [10], endothelin-1 [11] and bone morphogenic protein 4 [12].   
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IL-1β and IL-6 have been found to induce EMT changes in a variety of cell types.  Non-
small cell lung cancer cells treated with IL-1β underwent EMT [13].  IL-1β enhanced EMT in 
bronchial epithelial cells and alveolar epithelial carcinoma cells through TGF-β1 [14, 15].  IL-1β 
induced EMT through upregulation of Zeb1 in colon cancer cells [16]; and promoted EMT in 
head and neck squamous cell carcinoma through Zeb1 and Snail [17, 18].  IL-6 promoted EMT 
changes in breast cancer by upregulating the expression of Twist [19].  Hepatocellular carcinoma 
mesenchymal tumors and mesenchymal cell lines were associated with increased IL-6 expression 
and knockdown of IL-6 in cell lines resulted in increased E-cadherin expression and increased 
chemosensitivity [20].  IL-6 induction of EMT was mediated by STAT3 in cervical and lung 
cancers [21-23].  Interestingly, epidermal growth factor/epidermal growth factor receptor 
signaling induces EMT in cultures of OC cell lines and is also associated with enhanced 
expression and secretion of IL-6, resulting in increased cellular motility [24]. 
In addition to promoting a migratory and invasive phenotype, EMT may contribute to 
patient mortality by: conferring paclitaxel resistance in epithelial OC cells [25]; inducing 
myocyte differentiation into CD14+/KDR+ pro-angiogeneic cells thereby promoting tumor 
angiogenesis and vascularization [26] and; inducing the differentiation of stromal mesenchymal 
stem cells into tumor associated fibroblasts that support disease progression through matrix 
remodeling [27].  In this last context, it is interesting that both in vivo and in vitro studies 
indicate that IL-6 produced by stromal tumor associated fibroblasts enhances OC cell 
proliferation through activated STAT3 signaling [27].   
This study suggests consideration of unique treatment options for BRCA1 mutation 
carriers.  Treatment options should address the premalignant differences of mutation carriers 
before OC development, such as a possible prophylactic regimen of nitric oxide-releasing 
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NSAIDs (NO-NSAIDs) and/or cytokine-suppressive anti-inflammatory drugs that may prove 
useful in reducing the risk of BRCA1 mutation-associated OC.  Similarly, the chronic 
inflammatory microenvironment potentially associated with specific BRCA1 mutation may 
respond to anti-inflammatory drugs as seen in colorectal cancer where targeting inflammation 
modulated tumor biology and resulted in improvement in patient outcome [28].  Clinical studies 
have already reported that BRCA-associated OC tumors have a higher sensitivity to platinum-
containing treatments in comparison to mutation-negative tumors [29-31].  Therefore, enhanced 
treatment options may consider the addition of anti-inflammatory treatments, such as IL-1β 
neutralizing agents, in BRCA1-associated OCs in conjunction with standard therapy. 
Phase I and II clinical trials utilizing recombinant human IL-6 as adjuvant treatment in 
conjunction with chemotherapy increased OC patient platelet count alleviating thrombocytopenia 
[32, 33].  As stated earlier, IL-1 increases production of IL-6 [34, 35]; therefore, studies 
investigating the effect of IL-1 on the development of OC are clinically important.  A better 
understanding of IL-1 cytokines’ functions in relationship to OC may help to identify novel 
prophylactic drug treatments and/or treatments after disease occurrence.   
 Another phase I clinical trial showed recombinant human IL-1α treatment having minor 
antitumor effect in recurrent OC [36].  Nonetheless, clinical trials showed that recombinant 
human IL-1α treatment accelerated platelet recovery during chemotherapy and reduced 
carboplatin-induced thrombocytopenia  in patients with recurrent OC [37]; as well as in patients 
with ovarian and other cancer types (gastrointestinal, breast, melanoma, lung, head & neck, 
sarcoma, and prostate) who did not receive concomitant chemotherapy [38].  However, IL-6 is 
an effective hematopoietic growth factor and plays a direct role in megakaryocyte differentiation 
into platelets [32], and it may prove a better option than utilizing recombinant IL-1α.   
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In contrast, due to IL-1β’s cancer-promoting activities, inhibiting IL-1β function 
represents a promising new avenue for therapeutic intervention. Developing novel IL-1β 
antagonists that block IL-1β’s ability to bind to its receptor should suppress IL-1β’s VEGF-
mediated angiogenesis, invasiveness, and chemoresistance.  While published clinical trials of IL-
1β as a therapeutic target in treatment of cancer are limited, a phase I trial showed that treatment 
with recombinant human IL-1β elevated platelet levels in patients with gastrointestinal cancer 
[39].  IL-1β’s ability to increase platelet levels may be partially due to inducing production of IL-
6.  However, due to the aggressiveness of OC and IL-1β’s promotion of cancer progression, it 
may prove more beneficial to evaluate IL-1β as a treatment target rather than as a therapeutic 
agent.  Therefore, as a treatment target, effective agents would likely mimic the action of IL-1β’s 
natural antagonist, IL-1Ra, and/or to neutralize IL-1β.  Currently, a recombinant IL-1Ra, 
Anakinra, which blocks IL-1β and IL-1α from binding to their receptors, is used for the treatment 
of rheumatoid arthritis [40].  Likewise, the fusion glycoprotein, Rilonacept, which works by 
binding to IL-1α and IL-1β with high affinity to neutralize both molecules is yet another anti-
inflammatory therapy currently in use [40].  Lastly, Canakinumab, a fully humanized 
monoclonal antibody highly specific for IL-1β, is currently in clinical use to suppress 
inflammation [40].  Consequently, these anti-inflammatory medications may be valuable for 
their capability to reduce IL-1-induced disease processes that may initiate and promote OC. 
 Lastly, I began molecular, biochemical and structural characterization of the predicted 
BRCA1 185delAG truncated protein.  My analyses predict that BRAT is a small, hydrophobic 
protein located in the nucleus with potential DNA activating and/or inactivating capabilities.  
This work has illuminated possible mechanisms of 185delAG-dependent activity in the cell.  The 
production of a BRCA1 185delAG protein tool had not been accomplished previously, but is 
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now available and will allow for further protein characterization including ascertaining its 3D 
structure and functions in the cell.  Taken together, developing tools for the functional analyses 
of the different BRCA1 mutations may improve our understanding of the heterogeneity and 
etiology of OC, the most lethal gynecologic cancer.      
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